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1. Introduction 
Psoriasis is a systemic chronic, relapsing inflammatory skin disorder, with worldwide 
distribution, affects 1–3% of the world population, prevalence varies according to race, 
geographic location, and environmental factors (Chandran & Raychaudhuri, 2010; 
Christophers & Mrowietz, 2003; Farber & Nall, 1974). In Germany, 33,981 from 1,344,071 
continuously insured persons in 2005 were diagnosed with psoriasis; thus the one year 
prevalence was 2.53% in the study group. Up to the age of 80 years the prevalence rate 
(range: 3.99-4.18%) was increasing with increasing age and highest for the age groups from 
50 to 79 years The total rate of psoriasis in children younger than 18 years was 0.71%. The 
prevalence rates increased in an approximately linear manner from 0.12% at the age of 1 
year to 1.2% at the age of 18 years (Schäfer et al., 2011). In France, a case-control study in 
6,887 persons, 356 cases were identified (5.16%), who declared having had psoriasis during 
the previous 12 months (Wolkenstein et al., 2009). The prevalence of psoriasis analyzed 
across Italy showed that 2.9% of Italians declared suffering from psoriasis (regional range: 
0.8-4.5%) in a total of 4109 individuals (Saraceno et al., 2008). The overall rate of comorbidity 
in subjects with psoriasis aged less than 20 years was twice as high as in subjects without 
psoriasis. Juvenile psoriasis was associated with increased rates of hyperlipidaemia, obesity, 
hypertension, diabetes mellitus, Crohn disease and rheumatoid arthritis. The best-known 
noncutaneous condition associated with psoriasis is joint disease, mostly expressed as 
Psoriatic arthritis (PsA), (Mrowietz et al., 2007). Palmoplantar psoriasis is associated with 
significant quality-of-life issues. In 150 patients with palmoplantar psoriasis, 78 (52%) 
patients displayed predominantly hyperkeratotic palmoplantar lesions, 24 (16%) pustular, 
18 (12%) combination, and 30 (20%) had an indeterminate phenotype. In 27 (18%) patients, 
lesions were confined to the palms and soles. In all, 27 (18%) had mild, 72 (48%) moderate, 
and 51 (34%) severe disease involvement (Farley et al., 2009).  
2. Psoriasis in the clinic  
The disease has wide clinical spectra that range from epidermal (scaly) and vascular 
(thickened, erythematous) involvements of the skin, to the malignant form known as 
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generalized erythrodermia. Skin involvement is characterized by symmetrically distributed, 
well-demarcated plaques, its most common form named psoriasis vulgaris or plaque-type 
psoriasis. Two forms of psoriasis can be recognized: Type I psoriasis, characterized by been 
hereditary, dominant autosomic (60% penetration), onset: 16 years females, 22 years males; 
HLA-Cw6 positive (73.8% vs. 20.4 % in normal subjects). Type II psoriasis, characterized by 
been sporadic, major incidence 57-60 years, poor correlation with HLA-CW6 (27.3% vs. 
10.1% in controls). Psoriasis plaques with silvery scales present the Auspitz sign a pinpoint 
capillary bleeding when the scales are gently scraped away with a spatula or fingernail 
(Mrowietz, et al., 2007, 2009; Naldi & Mercuri, 2010). Psoriasis may also attack nails, 
(Augustin et al., 2010b;  Farber, & Nall , 1974), tendons, ligaments, fascia, and spinal or 
peripheral joints as the clinical form, inflammatory PsA similar to rheumatoid arthritis, but 
no rheumatoid factor present in the blood. PsA can be severely disabling, occurring in up to 
10–30% of patients with psoriasis, and is associated with HLA-B27 MHC Class I marker 
(Mrowietz et al., 2007). Psoriatic plaques induce pain and pruritus, generating discomfort 
and persistent insomnia. Quality of life decreases considerably because it is a physically 
disfiguring illness that disrupts social life, induces constant psychological stress, lowered 
self-esteem, and feelings of being socially ostracized. Common among many patients are the 
use of tranquilizers, sleeping pills, antidepressants, consumption of alcohol, and cigarette 
smoking (Choi & Koo 2003, Zeljko-Penavi´c et al. 2010, Wu et al., 2009, Van Voorhees & 
Fried 2009). Pruritus is an important symptom in psoriasis vulgaris may be severe and 
seriously affect the quality of life. 85% of psoriatic patients suffered from itching; the 
frequency of pruritus was daily and mean intensity was moderate. The results confirmed 
the need for a global study of psoriasis with regard to both the cutaneous manifestations 
and the itch symptom (Prignano et al., 2009). Ophthalmic complications of psoriasis are 
numerous and affect almost any part of the eye; however, they may be easily missed. 
Complications include direct cutaneous effects such as eyelid involvement and blepharitis, 
and immune mediated conditions such as uveitis (Rehal et al., 2011). In Spain, between 
January 2007 and December 2009 of a total of 661 patients included, 47.4% were diagnosed 
with nail psoriasis, which was 13.5% more prevalent in men. The group of patients with nail 
disease had more severe psoriasis (12.82 vs 8.22 points on PASI) and a longer disease 
duration (20.30 vs 13.94 years), and included a larger percentage of patients with psoriatic 
arthritis (29.7% vs 11.5%), a positive family history of the disease (53.7% vs 42.8%), and a 
body mass index greater than 30 (31.6% vs 23.9%). A larger percentage of the patients with 
nail disease had early-onset psoriasis (74.1% vs 65.5%) and fewer were carriers of the human 
lymphocyte antigen Cw0602 allele (33% vs 50.3%). Nail disease is frequent in psoriasis and 
is associated with greater severity of psoriasis and a larger number of comorbidities 
(Armesto et al., 2011). 
3. Psoriasis pathogenesis 
3.1 General concepts 
The introduction of the new concept of psoriatic disease represents a novel opportunity to 
better understand the pathogenesis of psoriasis and comorbidities (Scarpa et al., 2010). The 
disease is genetically determined with the involvement of multiple genes that interact with 
each other and with environmental factors (Elder, 2009). Analysis of patients demonstrated 
a strong association between psoriasis and all components of metabolic syndrome, which 
also explains comorbidities (Boehncke & Sterry, 2009). In early lesions, macrophages are 
present in the epidermis followed by monocytes, lymphocytes, and granulocytes with 
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formation of spongiform micro abscesses (Munro abscesses), more pronounced with disease 
activity, a hallmark of psoriasis. Physical trauma to the skin, results in a psoriatic lesion 
(Koebner phenomenon), which increases when the disease is active (Farber & Nall, 1974). 
The inflammatory process is immune mediated by unknown antigens through binding and 
specific activation and costimulation of T cells by antigen-presenting cells (APC), dendritic 
cells (DC), and macrophages in epidermis and dermis. A multimolecular complex is formed 
between APC and T cells: the immunological synapse, structured by major 
histocompatibility complex (MHC) receptors and T-cell receptors (TCR), with the following 
costimulatory molecules: lymphocyte functional antigen (LFA-1 and LFA-3), intercellular 
adhesion molecule (ICAM- 1), cluster of differentiation CD2, CD28, CD80, (Mrowietz, & 
Reich, 2009). Epidermal keratinocytes are highly active immunological cells, controlling the 
acute and the chronic phase of skin inflammation by cytokine/chemokine production and 
surface molecule expression, which lead to inflammatory infiltrate in the whole skin including 
the upper layers of the epidermis, perpetuating the skin disorder (Albanesi & Pastore, 2010). 
Dendritic cells and effector T-cells are central in the development of the psoriastic lesion, and 
cytokines produced by these cells stimulate keratinocytes to proliferate and increase the 
migration of inflammatory cells into the skin, promoting epidermal hyperplasia and 
inflammation (Monteleone et al., 2011). Psoriasis is a common chronic inflammatory disease of 
the skin and joints. Autoantibodies have been reported in psoriasis patients. Anti-nuclear 
antibody and antibody to double-stranded deoxyribonucleic acid, rheumatoid factor, anti-
thyroid microsomal antibody (anti-TMA) were studied. About 28.8% of psoriasis cases were 
positive for at least one autoantibody. Age of onset and types of psoriasis had significant 
association with gender. Anti-double-stranded deoxyribonucleic acid and anti-thyroid 
microsomal antibody had significant association with types of psoriasis. Gender wise 
distribution of psoriasis in age group had significant association with anti-TMA. 
Autoantibodies are found to be present in psoriasis patients or latent autoimmune diseases 
develop in psoriasis patients without any clinical symptoms (Singh et al., 2010). 
3.2 Blood vessels in psoriasis pathogenesis 
Angiogenesis is essential for embryo development as well as for wound healing and 
progression of a number of diseases such as cancer, inflammatory conditions, eye diseases, 
psoriasis, and rheumatoid arthritis (RA) in the adult. Current paradigms explain blood 
vessel growth entirely by sprouting angiogenesis or by vessel splitting through so called 
intussusceptive angiogenesis. However, these mechanisms are mainly derived from 
experiments on the developing embryo while less is known about angiogenesis in the adult 
during, e.g., wound healing, tumor growth, and inflammation. Blood vessel growth in the 
adult can be induced and directed by mechanical forces that naturally develop during 
healing or remodeling of tissues (Kilarski  & Gerwins, 2009). It is regulated by pro- and anti-
angiogenic molecules, and was only implicated in few diseases, such as, cancer, arthritis, 
and psoriasis, now its research offers a potential to cure a variety of diseases such as 
Alzheimer's and AIDS. Angiogenesis may have an impact similar to that of antibiotics had 
in the twentieth century (Bisht et al., 2010). Angiogenic factors, such as vascular endothelial 
growth factor (VEGF), may dominate the activity of anti-angiogenic factors and accelerate 
angiogenesis in psoriatic skin. Small peptides with homologies to pigment epithelium 
derived factor (PEDF) show anti-angiogenic potential for the topical treatment for psoriasis. 
The specific low-molecular weight peptides (MW<850 Da) penetrated the skin and showed 
significant anti-angiogenic activity in vitro. Topical application of these peptides in a severe 
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combined immunodeficient mouse model of psoriatic disease led to reduced angiogenesis 
and epidermal thickness (Abe et al., 2010). VEGF is overexpressed in lesional psoriatic skin 
and its serum levels are significantly elevated in patients with moderate to severe disease. 
Thirty patients with moderate to severe psoriasis and 10 healthy controls were subjected to 
baseline evaluation of VEGF. Patients were divided into three groups according to the 
received treatment: psoralen plus ultraviolet A (PUVA) thrice weekly (group 1), acitretin 50 
mg daily (group 2), and combined PUVA twice weekly and acitretin 25 mg daily (group 3). 
Treatment continued for 16 weeks or up to clinical cure. Every patient was subjected to 
severity evaluation by PASI and measurement of serum VEGF before and after treatment. 
Mean serum levels of VEGF were significantly elevated in patients (327 ± 66.2 pg/mL) than 
control subjects (178 ± 83.4 pg/mL). A highly significant correlation was found between 
VEGF and PASI score. VEGF is important in the pathogenesis of psoriasis, and could serve 
as a good indicator of disease severity and control (Nofal et al., 2009). 
3.3 T cells and cytokines in psoriasis 
The chemokine/chemokine receptor network is an integral element of the complex system 
of homeostasis and immunosurveillance. Initially studied because of their role in 
coordinating tissue-specific migration and activation of leucocytes, chemokines have been 
implicated in the pathogenesis of various malignancies and diseases with strong 
inflammatory components. There is a critical involvement of chemokine receptor 
interactions in the immunopathogenesis of classical inflammatory skin disorders such as 
psoriasis and atopic dermatitis, as well as neoplastic diseases with a T-cell origin, such as 
mycosis fungoides (Lonsdorf et al., 2009). In psoriasis, leukocytes that infiltrate skin lesions 
have been shown to be involved in the pathogenesis of this disease. The presence of 
CXCR3+ T lymphocytes in psoriatic lesional skin, have suggested a role of this receptor in 
the recruitment of T cells into the lesion. The mRNA levels of CXCR3 and its ligands, 
CXCL9-11, were significantly elevated by real-time reverse transcriptase-polymerase chain 
reaction in psoriatic lesions, as compared to non-lesional samples. The number of CXCR3+ 
cells was low in non-lesional tissues, wile the number of both epidermal and dermal 
CXCR3+ cells increased in lesional compared with non-lesional tissues. The majority of 
CXCR3+ cells were located in the dermis of the lesional skin and 74% were CD3+ T 
lymphocytes. A small number of CXCR3+ cells were CD68+ myeloid cells and all BDCA-2+ 
plasmacytoid dendritic cells were CXCR3+ (Chen et al., 2010).  
Psoriasis is associated with chronic inflammation and it often coexists with inflammatory 
arthritis (Nestle et al., 2009) in which IL-33 has been implicated (Xu et al., 2008). IL-33 is one of 
the newest members of the IL-1 family of inflammatory cytokines (Castellani et al., 2009) and 
can mediate IgE-induced anaphylaxis in mice (Pushparaj et al., 2009). IL-33 also induces 
release of IL-6 from mouse bone marrow-derived cultured mast cells (Moulin et al., 2007) and 
IL-8 (Iikura et al., 2007). IL-33 augments SP-stimulated VEGF release from human mast cells 
and IL-33 gene expression is increased in lesional skin from patients with psoriasis 
(Theoharides et al., 2010b). Mast cells may, therefore, be involved in the pathogenesis of 
psoriasis and other inflammatory skin diseases. Macrophage migration inhibitory factor (MIF) 
is implicated in a range of pathological conditions, including asthma, rheumatoid arthritis, 
atherosclerosis, inflammatory bowel disease and cancer. In the field of dermatology, MIF is 
believed to be a detrimental factor in diseases such as systemic sclerosis, atopic dermatitis, 
psoriasis, eczema and UV radiation damage (Gilliver et al., 2011).  
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CD4+ effector cells have been categorized into four types: 1)- T helper1 cells produce IFN-, 
TNF-ǃ, lymphotoxin and IL-10; 2)- T helper2 cells produce IL-4, IL-5, IL-10, IL-13, IL-21, IL-
31; 3)- T helper3, or regulatory T-cells, produce IL-10, TGF-ǃ and IL-35;  4)- T helper-17 cell 
produces IL-17, IL-17A, IL-17F, IL-21, IL-26 and CCL20. By producing IL-17 and other 
molecules, Th17 contributes to the pathogenesis of multiple autoimmune diseases including 
psoriasis, allergic inflammation, rheumatoid arthritis, autoimmune gastritis, inflammatory 
bowel disease and multiple sclerosis. IL-17-producing CD4+ T lymphocytes (Th17) are 
currently considered relevant participants in the pathogenesis of psoriasis skin lesions, 
together with IL-17-producing CD8+ T cells, which are also present at the psoriatic plaque, 
and produce TNF and IFN  as well as IL-17, IL-21, and IL-22. These cells are refractory to 
Tregs but show a proliferative response to anti-CD3/CD28 stimulation that is enhanced by 
IL-12 and IL-15. Blocking of TNF- activity inhibits TCR-mediated activation and IL-17 
production. CD8+IL-17+ T cells are cytotoxic cells that display TCR/CD3-mediated 
cytotoxic abilities to kill target cells (Ortega et al., 2009). Human Th17 cells and IL-23 play an 
important role, in the context of Th17 cell dependent chronic inflammation in psoriasis (Di 
Cesare et al., 2009). Th17 cells, is now into the centre of psoriasis pathogenesis. These cells 
secrete interleukin (IL)-17, IL-21 and IL-22, the latter of which appears to significantly 
contribute to the epidermal changes observed in this disease. Differentiation and 
maintenance of Th17 cells depends on IL-23 and transforming growth factor (TGFǃ) secreted 
by activated monocytes or macrophages within the dermal compartment (Kunz, 2009). 
Factors such as climate, physical trauma, drug, stress and infections (Streptococcus, human 
immunodeficiency virus) are known to trigger psoriasis. T helper (Th) 17 mechanisms of 
how these cells traffic into inflamed skin are unknown. By immunostaining for interleukin 
(IL)-17A and IL-22, it has been shown numerous cells present in psoriasis lesions that 
produce these cytokines. Th17 cytokines (IL-17A, IL-22, and tumor necrosis factor (TNF) 
markedly increased the expression of CC chemokine ligand (CCL)-20, a CC chemokine 
receptor (CCR)6 ligand, in human keratinocyte monolayer and raft cultures in a dose- and 
time-dependent manner. In mice that subcutaneous injection with recombinant IL-17A, IL-
22, or TNF- led to the upregulation of both CCL20 and CCR6 expression in skin as well as 
cutaneous T-cell infiltration. Taken together, these data show that Th17 cytokines stimulate 
CCL20 production in vitro and in vivo, and thus provide a potential explanation of how 
CCR6-positive Th17 cells maintain their continual presence in psoriasis through a positive 
chemotactic feedback loop (Harper et al., 2009).  
The skin harbors a complex and unique immune system that protects against various 
pathologies, such as infection and cancer. Several cell populations are involved in this 
immune regulatory function, including CD4+ T cells that coexpress the transcription factor 
Foxp3, known as Tregs, and cells with immune-regulatory function known as myeloid-
derived suppressor cells (MDSCs). Although their depletion may serve to augment 
immunity, expansion of these cells may be used to suppress excessive immune reactions 
(Ilkovitch, 2011). 
Production and uptake of inducible HSP70 by keratinocytes may critically influence the 
chronic course of inflammatory skin diseases. Human keratinocytes release high levels of 
inducible heat shock protein (HSP)-70 that enhances peptide uptake. The stress-inducible 
chaperone HSP70 is considered a ‘danger signal’ if released into the extracellular 
environment. It has been proposed to play a role in the pathogenesis of skin diseases such as 
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psoriasis and lupus erythematosus (LE). Living keratinocytes are an important source of 
HSP70 in the skin and release more HSP70 than fibroblasts, macrophages or lymphocytes. 
Keratinocytes also bind and internalize HSP70 ⁄ HSP70–peptide complexes a process 
enhanced by TNF and IL-27. No difference with regard to HSP70 release or uptake was 
observable between keratinocytes from healthy donors or patients with cutaneous LE. 
Keratinocytes pulsed with HSP70–peptide complexes significantly increased IFN 
production by autologous T cells which influence the chronic course of inflammatory skin 
diseases (Wang et al., 2011). 
3.4 Mast cells and natural killer cells in plaque psoriasis 
Psoriasis is a common inflammatory skin disease triggered by dysregulated immune 
response and characterized by hyperproliferation and altered differentiation of 
keratinocytes, as well as mast cell accumulation and activation (Harvima et al., 2008). Mast 
cells are increased in lesional psoriatic skin (Özdamar et al., 1996), and have important 
functions as sensors of environmental and emotional stress (Paus et al., 2006; Harvima et al., 
1993) possibly due to direct activation by corticotrophin release hormone (CRH) and related 
peptides secreted under stress (Theoharides et al., 2004; Katsarou-Katsari et al., 1999;   
Church & Clough 1999; Theoharides et al., 2010; Harvima et al., 1993; Fortune et al., 2005; 
Harvima et al., 1996). Psoriasis is associated with increased serum CRH and decreased 
lesional skin CRHR-1 gene expression (Tagen et al., 2007). Formation of psoriatic lesions is 
elicited by the complex cellular and cytokine network arising from the pathogenic 
interactions between keratinocytes and components of innate and acquired immune system. 
Natural killer T (NKT) cells are a heterogenous T-cell lineage that has been implicated in the 
pathogenesis of various autoimmune diseases including psoriasis. Due to the numerous 
functions of NKT cells that link innate and adaptive immunity, their role in psoriasis is still 
elusive (Peternel & Kastelan, 2009). NKT cells are best known for their ability to recognize 
and kill tumor cells and virally infected cells and by production of large amounts of some 
cytokines, such as IFN. In addition to the functions in cancer and autoimmunity, 
contributions from NK cells to allergies and various skin diseases have emerged. In patients 
with allergic diseases, the production of TH2 cytokines by NKT cells contributes to the 
known immune deviation. In patients with psoriasis, their pathophysiologic role seems to be 
especially the production of IFN. NK cell overactivation can be found in patients with 
alopecia areata and pemphigus vulgaris (von Bubnoff et al., 2010). 
3.5 Psychosomatics, neuropeptides, central and peripheral nervous system, nerve 
growth factor, and skin  
In the central nervous system (CNS), neuroinflammation is due to local production of IL-17 
in the brain. Inflammation in various tissues is achieved by secreted IL-17, IL-17A, and IL-17 
F due to their proinflammatory effects on cellular targets, which include endothelial cells, 
epithelial cells, fibroblasts, keratinocytes, monocytes/macrophages and osteoclasts. Under 
CNS inflammatory conditions, microglia, which act as antigen presenting cells, produce IL-
1b and IL-23. Acting in an autocrine manner, these cytokines may further induce IL-17 
expression in microglia, contributing to neuroimmune disorders. Another inflammatory 
pathway involving IL-17 is the IL-17-induced activation of MMP-3, which recruits 
neutrophils to the site of inflammation (Vojdani &, Lambert, 2009).  
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Outpatients experiencing exacerbation of psoriasis in the last 6 months (n = 110) were 
compared with outpatients affected by skin conditions in which psychosomatic factors are 
believed to play a minor role (n = 200). In comparison with controls the patients with 
psoriasis reported more stressful life events. Also, patients with psoriasis were more likely 
to score higher on both anxiety and avoidance attachment scale and perceived less support 
from their social network than did the comparison subjects (Janković et al., 2009). 32 
consecutive outpatients (9 males and 23 females), age M = 43.9 with psoriasis were 
examined by a team of dermatologists, psychiatrists and a psychologist using a standard set 
of methods. In addition, 32 patients with other chronically occurring skin diseases, 
including 11 males and 21 females, age M = 31.6, were also examined and formed the 
control group. The point prevalence of mental disorders was significantly higher in the 
psoriatic group: 20 (62.5%) versus 5 (15.62%) in the control group. In all of the cases, 
affective disorders were diagnosed. Mild anxiety disorders were additionally found in 10 
psoriatic patients (31.25%) and in 2 controls (6.25%). The level of depression was much 
higher in the study group than in the control group. Neurotic symptoms were also 
significantly more intense in the psoriatic group (54.37± 40.99) than in the control group 
(35.28±23.96). The results imply the need for the careful examination of the mental state of 
patients with psoriasis in order to offer and provide treatment of any concomitant 
psychiatric conditions (Parafianowicz et al., 2010).  
Neuropeptides (Saraceno et al., 2006) especially substance P (SP) (Remröd et al., 2007) are 
involved in the pathogenesis of psoriasis. In particular, SP reactive fibers are localized close 
to mast cells (Naukkarinen et al., 1996). SP can stimulate mast cells (Kawana et al., 2006; 
Kandere-Grzybowska et al., 2003) and contributes to inflammation (Leeman & Ferguson, 
2000; O'Connor et al., 2004). SP-positive nerve fibers are denser in psoriatic lesions and have 
an increased number of mast cell contacts compared to normal skin (Chan et al., 1997; 
Al'Abadie et al., 1995). The nervous system contributes to inflammatory skin diseases. The 
neuronal contribution to psoriasis at the remission and exacerbation phases were analyzed 
by the expression of the neuronal markers protein gene product 9.5 (PGP 9.5), growth-
associatedprotein-43 (GAP-43) and substance P, in addition to its receptor (R), neurokinin-
1R (NK-1R) in psoriatic skin from seven female patients at remission and exacerbation, 
using immunohistochemistry. The number of epidermal PGP 9.5 immunoreactive nerve 
fibres in the involved skin during exacerbation was decreased compared to involved skin at 
remission and non-involved skin at the exacerbation phase. GAP-43-positive nerve fibres 
were decreased in the involved skin in contrast to non-involved skin, during exacerbation. 
Substance P expression was seen on both immunoreactive nerve fibres and cells with a 
down-regulation in the number of positive nerve fibres in the involved skin compared to 
non-involved skin, at the exacerbation phase. The number of substance P-positive cells was 
slightly lower in the involved skin at exacerbation than at remission. The number of NK-1R 
immunoreactive cells was increased in the involved skin in contrast to non-involved skin, at 
the exacerbation phase. These findings suggest a crosstalk between the nervous system and 
inflammation during psoriasis exacerbation in the form of an altered expression of nerve 
fibres, substance P and its NK-1R(El-Nouretal.,2009). A contributing role of nerve growth 
factor (NGF) mediated neuroimmunologic mechanisms has provided a new dimension in 
the understanding of various cutaneous and systemic inflammatory diseases and 
comorbidities. Recent evidence implicates NGF as a key mediator of inflammation and pain. 
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NGF influences an inflammatory reaction by regulating neuropeptides, angiogenesis, cell 
trafficking molecules, and T cell activation. The recognition of a pathologic role of NGF and 
its receptor system has provided an attractive opportunity to develop a novel class of 
therapeutics for inflammatory diseases and chronic pain syndromes (Raychaudhuri SK, &  
Raychaudhuri  SP , 2009). Psoriasis is characterized by keratinocyte hyperproliferation and 
reduced apoptosis, leading to an increased epidermal turnover. Interestingly, NGF that is 
both a mitogen and a survival factor for keratinocytes, is overexpressed in psoriatic lesions 
as well as in psoriatic keratinocytes, (Fantini et al., 1995; Raychaudhuri et al., 1998) and its 
high-affinity receptor TrkA, that is located only in basal keratinocytes in healthy skin, is 
expressed throughout all epidermal layers in psoriasis (Pincelli, 2000). On the other hand, 
P75NTR that plays a proapoptotic role in keratinocytes, is absent in psoriatic keratinocytes. 
The rate of apoptosis in psoriatic transit amplifying (TA) cells is significantly lower as 
compared to TA cells from normal epidermis. On the contrary, in psoriasis, NGF and Trk 
upregulation associated with reduced P75NTR expression result in increased keratinocyte 
proliferation and reduced apoptosis, thus favoring epidermal thickness, a typical feature of 
this dermatosis (Truzzi et al., 2011). The question of lymphocyte being an initiator of 
psoriatic events remains open. Plaque symmetry, stress-induced onset or exacerbations, 
pruritus, and possibility of generalization, suggest a role of the nervous system and 
neurogenic inflammation in pathogenesis. A key to understanding the role of melanocyte in 
psoriasis is their ability to act as regulatory cell in maintaining epidermal homeostasis. It has 
been suggested melanocyte, acting as a local ‘‘stress sensor”, provide communicatory link 
between CNS and skin. The disease probably begins with so far unknown signal directed 
through neuronal network to the melanocyte, placed in the center of epidermal unit. That 
signal governs keratinocyte cellular activities and lead to reactive abnormal epidermal 
differentiation and hyperproliferation. Increased proliferation of basal keratinocytes and 
high metabolic demands creates angiogenesis in papillary dermis and elongation of dermal 
papillae. Stimulated melanocytes and basal keratinocytes become an important source of 
proinflammatory cytokines that attract lymphocytes into the dermis (Brajac et al., 2009). 
Pruritus involves skin surface receptors, peripheral and central nerves and specific brain 
regions. Peripheral unmyelinated C nerve fibres are stimulated. These nerves relay the itch 
signal to an ipsilateral spinal nucleus. At the same spinal level, involved nerve fibres carry 
the signal to the thalamus while giving off fibres to the cerebral aqueduct; the thalamus 
relays the signal to the somatosensory cortex. Psoriasis, has been named as the itch that 
scales; its importance is shown by the observation that sensory denervation leads to plaque 
resolution. Characteristic areas of psoriatic itch are the buttocks, extensor surfaces of the 
knees and elbows, and the ears and scalp. In psoriasis, 41–80% of patients have daily itch. 
Neuropeptide Y is inhibitory with respect to itch and decreased levels are seen in patients 
with psoriasis, which may explain the increased pruritus in psoriasis. Itch description varies 
in patients with psoriasis, ranging from stinging to burning to itch that affects sleep 
(Langner & Maibach, 2009) 
3.5.1 Oxidative stress in skin disorders 
The involvement of oxidative stress in the pathogenesis of various skin disorders has been 
suggested for decades. However, few clinical studies have assessed oxidative stress in skin 
diseases. The easiest and least invasive method to assess oxidative stress in patients may be 
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the measurement of oxidation products in urine. Nitrate as a metabolite of nitric oxide, 
malondialdehyde as a major lipid oxidation product, and 8-hydroxydeoxyguanosine (8-
OHdG) as a DNAoxidation marker. Urinary nitrate and 8-OHdG levels, but not 
malondialdehyde, were significantly higher in psoriasis patients than those in healthy 
controls. The severity and extent of both psoriasis and atopic dermatitis significantly 
correlated with urinary nitrate level and malondialdehyde level, but it did not correlate with 
urinary 8-OHdG level (Nakai et al., 2009). Psoriatic keratinocytes are poorly differentiated 
and hyperproliferative. Low concentrations of nitric oxide (NO) induce keratinocyte 
proliferation, while high concentrations induce differentiation. The NO-producing enzyme 
inducible NO synthase is overexpressed in psoriatic skin, but so is arginase. The 
overexpressed arginase competes for arginine, the common substrate for both enzymes, and 
may reduce NO production. Arginase is overactive in psoriatic skin, leading to a relative 
increase in the consumption of arginine (Abeyakirthi et al., 2010). Oxidative stress (OS) and 
increased free-radical generation have been linked to skin inflammation in psoriasis 
(Rashmi et al., 2009). Skin is a major target of oxidative stress mainly due to reactive oxygen 
species (ROS) originating from the environment and skin metabolism itself. Although 
endogenous antioxidants attenuate the harmful effects of ROS, increased or prolonged 
presence of free radicals can override ROS defense mechanisms and mediate numerous 
cellular responses that contribute to the development of a variety of skin disorders, 
including psoriasis. The cellular signaling pathways such as mitogen-activated protein 
kinase/activator protein 1, nuclear factor κB, and Janus kinase–signal transducers and 
activators of transcription are known to be redox sensitive and proven to be involved in the 
progress of psoriasis (Zhou et al., 2009). The skin is permanently exposed to physical, 
chemical, and biological aggression by the environment, and chronic inflammatory events 
taking place in the skin are accompanied by abnormal release of pro-oxidative mediators. 
Homeostatic systems are active in the skin to maintain the redox balance and also to 
counteract abnormal oxidative stress. There is evidence that a local and systemic redox 
dysregulation accompanies the chronic inflammatory disorder events associated to 
psoriasis, contact dermatitis, and atopic dermatitis. Several treatments for the therapy of 
chronic inflammatory skin disorders are based on the application of strong physical or 
chemical oxidants onto the skin, indicating that, in selected conditions, a further increase of 
the oxidative imbalance may lead to a beneficial outcome (Pastore & Korkina, 2010). 
3.6 Genetics in skin psoriasis  
Psoriasis is a complex inflammatory skin pathology probably of autoimmune origin. Several 
cell types are perturbed in this pathology, and underlying signaling events are complex and 
still poorly understood. Network-based analysis revealed similarities in regulation at both 
proteomics and transcriptomics level. A group of transcription factors are responsible for 
overexpression of psoriasis genes and a number of previously unknown signaling pathways 
may play a role in this process. Investigation of proteomics and transcriptomics data sets on 
psoriasis revealed versatility in regulatory machinery underlying pathology and showed 
complementarities between two levels of cellular organization (Piruzian et al., 2010). The 
linkage analysis has been used to identify multiple loci and alleles that confer risk of the 
disease. Some other studies have focused upon single nucleotide polymorphisms (SNPs) for 
mapping of probable causal variants. Other studies, using genome-wide analytical 
techniques, tried to link the disease to copy number variants (CNVs) that are segments of 
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DNA ranging in size from kilobases to megabases that vary in copy number, an important 
element of genomic polymorphism, predisposing to a variety of human genetic diseases. 
Genotyping of single nucleotide polymorphisms, copy number variations and statistical 
tools have become extremely important to researchers for understanding the pathogenesis 
and molecular mechanism of psoriasis. Microarray analysis of psoriasis patients highlights 
the variability in gene expression occurring between individual patients, probably on the 
basis of their age, ethnicity, sex, genetics, skin types and environmental influences. The gene 
expression data and their analyses have suggested that psoriasis is a chronic interferon- 
and T cell mediated immune disease of the skin with imbalances in epidermal cellular 
structures (Al Robaee, 2010). Psoriasis is a systemic disease of the skin, nails, and joints, with 
an acknowledged but complex genetic basis. Early genome-wide linkage studies of psoriasis 
focused on segregation of microsatellite markers in families; however, the only locus 
consistently identified resided in the MHC. Subsequently, several groups mapped this locus 
to the vicinity of HLA-C, and two groups have reported HLA-Cw6 itself to be the major 
susceptibility allele. The development of millions of SNP, coupled with the development of 
high-throughput genotyping platforms and a comprehensive map of human haplotypes, 
has made possible a genome-wide association approach using cases and controls rather than 
families. A collaborative genome-wide association study of psoriasis involving thousands of 
cases and controls revealed association between psoriasis and seven genetic loci: HLA-C, 
IL12B, IL23R, IL23A, IL4/IL13, TNFAIP3, and TNIP1 (Elder et al., 2010). 
3.7 Infections and psoriasis 
Invasive streptococcal infections may have been a factor in psoriasis becoming a common 
skin disease in some parts of the world. Many of the candidate genes linked to psoriasis are 
associated with the acquired or innate immune system, which are also important in host 
defence to invasive streptococcal infections. High rates of positive streptococcal throat 
swabs among patients with chronic plaque psoriasis suggest that they are efficient at 
internalizing/carrying beta-haemolytic streptococci. Internalization of streptococci in the 
throat is dependent upon the transforming growth factor (TGF)-ǃ/fibronectin/-5 ǃ-1 
integrin pathway that also appear to be operative in psoriasis. It has been postulated that 
some of the genotypic/phenotypic changes in different immunological pathways in 
psoriasis, including the acquired T-cell response, the innate immune response, the TGF-
ǃ/fibronectin/-5 ǃ-1 integrin pathway and the Th17 cell system, confer protection against 
mortality during epidemics of invasive streptococcal infections, heightened efficiency in 
internalizing and allowing carriage of streptococci as well as predisposition to the 
development of psoriasis (McFadden et al., 2009). 
4. Psoriatic comorbidities 
Psoriasis has been associated with a number of behavioral and systemic comorbidities, 
including psoriatic arthritis, anxiety, depression, obesity, hypertension, diabetes mellitus, 
hyperlipidemia, metabolic syndrome, smoking, cardiovascular disease, alcoholism, Crohn's 
disease, lymphoma, and multiple sclerosis. Many of these conditions have a similar 
immunologic pathogeneses. Canadian and international studies have not only confirmed 
the presence of these comorbidities but also have demonstrated that patients with psoriasis 
have a significantly reduced life span. Given that patients with psoriasis are often unaware 
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of their comorbidities, they should be screened for these conditions and treated if required 
by their dermatologist and/or primary care physician. It is important to keep in mind that 
the comorbidities and drugs used to treat them have an impact on the choice of antipsoriatic 
treatment. In addition, comorbidities often preclude the use of traditional systemic agents. 
Recent studies have demonstrated that patients with preexisting comorbidities can be safely 
and effectively treated with biologic therapy. Furthermore, literature is evolving to suggest 
that better control of psoriasis might decrease cardiovascular mortality and prolong life 
(Guenther & Gulliver, 2009). In Taiwan, 51,800 psoriasis cases were identified (prevalence: 
0.235%) and 17.5% of cases were severe psoriasis type. Psoriasis was associated with a 
significantly increased prevalence ratio (RR) for hypertension (1.51), diabetes (1.64), 
hyperglyceridaemia (1.61), heart disease (1.32), hepatitis B viral infection (1.73),  hepatitis C 
viral infection (2.02), rheumatoid arthritis (3.02), systemic lupus erythematosus (6.16), 
vitiligo (5.94), pemphigoid (14.75), pemphigus (41.81), alopecia areata (4.71), lip, oral cavity 
and pharynx cancer (1.49), digestive organs and peritoneum cancer (1.57), depression (1.50), 
fatty liver (2.27), chronic airways obstruction (1.47), sleep disorder (3.89), asthma (1.29), and 
allergic rhinitis (1.25). Conversely, psoriasis was not associated with an increased risk of 
Crohn's disease. Psoriasis was associated with a significantly increased risk of comorbidities, 
especially for those patients with moderate to severe disease (Tsai et al., 2011). 
Epidemiological studies have shown that, in patients with psoriasis, associated disorders 
may occur more frequently than expected. Such comorbidities include PsA, inflammatory 
bowel disease, obesity, diabetes, and cardiovascular disease (CVD), several cancer types, 
and depression. Comorbidities often become clinically manifest years after onset of psoriasis 
and tend to be more frequently seen in severe disease (Naldi & Mercuri, 2010). In particular, 
nonalcoholic fatty liver disease affects about 50%, Crohn’s disease 0.5% and celiac disease 
0.2 to 4.3% of patients with psoriasis. The presence of comorbidities has important 
implications in the global approach to patients. In particular, traditional systemic 
antipsoriatic agents could negatively affect cardio-metabolic comorbidities as well as 
nonalcoholic fatty liver disease and may have important interactions with drugs commonly 
used by psoriasis patients. Moreover, patients with psoriasis should be encouraged to 
drastically correct their modifiable cardiovascular and liver risk factors, in particular 
obesity, alcohol consumption, and smoking habit, because this could positively affect 
psoriasis, PsA and their life expectance (Gisondi et al., 2010). Clinical measures of disease 
activity were related to fatigue over time; however, these relationships disappeared in the 
context of patient reported physical disability and pain. Patient reported measures of 
physical disability, pain, and psychological distress were most closely related to higher 
“Modified Fatigue Severity Scale” (mFSS) scores (greater fatigue) across clinic assessments. 
Fatigue was found to vary over time, at least when assessed at yearly intervals. In general, 
measures of clinical and functional status at the current visit were more predictive of change 
in mFSS scores in between previous and current visits than change scores between visits. 
Comorbid fibromyalgia and hypertension were also associated with greater fatigue across 
multiple visits and with change in fatigue between visits. A combination of factors is 
associated with fatigue in PsA (Husted et al., 2010) . 
Higher percentage frequency in PsA than psoriasis patients was found in hypertension, 
vascular diseases, intestinal diseases, infections, gastritis, cardiac arrhythmia, gallstones in 
gallbladder, osteoporosis, hyperuricemia and epilepsy. Up to 7-8 comorbidities were found 
in both psoriasis and PsA patients together in the same subject, thus, psoriasis is a systemic 
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disease, induced by cytokines in all body organs, being expressed in each tissue according to 
genetic and environmental factors due to shared inflammatory pathways. Development of 
psoriasis and PsA is centered in the blood vessels behavior. Both diseases start by 
proliferation of blood vessels after up-regulation of VEGF, TGFǃ and other angiogenic 
factors. Clinical remission in psoriatic lesions also starts by decrease proliferation of blood 
vessels, after treatment with leishmania antigens (O’Daly, 2011, manuscript in press). 
4.1 Cardiovascular disease  
Psoriasis and atherosclerosis are interrelated; pathogenic mechanisms are shared between 
the two diseases inducing inflammation. Within the lymph nodes, antigen-presenting cells 
activate naive T-cells to increase expression of LFA-1 following which activated T-cells 
migrate to blood vessel and adhere to endothelium. Extravasation occurs mediated by LFA-
1, LFA-3 and ICAM-1 or CD2. Activated T-cells interact with dendritic cells, macrophages 
and keratinocytes in psoriasis or with smooth muscle cells in blood vessels, in 
atherosclerosis. These cells further secrete chemokines and cytokines that contribute to the 
inflammatory environment, resulting in the formation of psoriatic plaque or atherosclerotic 
plaque (Ghazizadeh et al., 2010). Patients with psoriasis are at increased risk for severe 
vascular disease (Shelling et al., 2008). This increased risk is imparted by both a predilection 
for patients with psoriasis to have traditional vascular disease risk factors  like diabetes, 
hypertension, smoking, dyslipidemia (Federman et al., 2009) and the recognition that 
psoriasis itself is an independent risk factor for vascular disease (Gelfand et al., 2011). The 
latter is probably mediated by systemic inflammation associated with psoriasis, similar to 
that observed in patients with rheumatoid arthritis. Patients whose psoriasis develops at a 
young age and those with more severe disease are at the greatest risk (Gelfand et al., 2011). 
Initial psoriasis comorbidity studies focused on cardiovascular disease, but atherosclerosis is 
a systemic disease (Prodanovich et al., 2009). It is reasonable to postulate that if the 
likelihood of myocardial infarction is increased in patients with psoriasis, other 
manifestations of atherosclerosis, such as stroke, might also be more common in these 
patients. Stroke is a leading cause of mortality, and many who survive experience functional 
disability, with up to 30% being permanently disabled and 20% requiring institutional care 
(Rosamond et al., 2008; Rico et al., 2009). A cohort study of patient’s ≥18 years from 1987 to 
2002, were analyzed. Patients with a psoriasis code and a history of systemic therapy 
consistent with severe psoriasis (n=3603) were compared with patients with no history of 
psoriasis (n=14,330). Patients with severe psoriasis were at increased risk of death from 
cardiovascular disease hazard ratio (HR) (1.57), malignancies (1.41), chronic lower 
respiratory disease (2.08), diabetes (2.86), dementia (3.64), infection (1.65), kidney disease 
(4.37), and unknown/missing causes (1.43). The absolute and excess risk of death was 
highest for cardiovascular disease (61.9 and 3.5 deaths per 1000 patient-years, respectively). 
Severe psoriasis is associated with an increased risk of death from a variety of causes, with 
cardiovascular death being the most common aetiology (Abuabara et al., 2010). 
Psoriasis patients of a health-maintenance organization were compared with enrollees 
without psoriasis regarding the prevalence of hypertension in a case-control study. The 
study included 12,502 psoriasis patients over the age of 20 years and 24,285 age- and sex-
frequency-matched controls. The prevalence of hypertension was significantly higher in 
psoriasis patients than controls (38.8% vs. 29.1%, respectively). In a multivariate analysis, 
hypertension was associated with psoriasis after controlling for age, sex, smoking status, 
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obesity, diabetes, non-steroidal anti-inflammatory drugs (NSAIDs) and use of Cox-2 
inhibitors (odds ratio: 1.37). The results of this study support the previously noted 
association between psoriasis and hypertension (Cohen et al., 2010). 
Treatment with multiple anti-hypertensives was significantly associated with the presence 
of psoriasis using univariate and multivariable analysis, after adjusting for diabetes, 
hyperlipidemia, and race. Compared to hypertensive patients without psoriasis, psoriasis 
patients with hypertension were 5 times more likely to be on a monotherapy 
antihypertensive regimen, 9.5 times more likely to be on dual antihypertensive therapy, 16.5 
times more likely to be on triple antihypertensive regimen, and 19.9 times more likely to be 
on quadruple therapy or centrally-acting agent in multivariable analysis, after adjusting for 
traditional cardiac risk factors. Psoriasis patients appear to have more difficult-to-control 
hypertension compared to non-psoriatic, hypertensive patients (Armstrong et al., 2011).  
The cardiovascular risk factors in patients with psoriasis and the association between 
psoriasis and coronary artery, cerebrovascular, and peripheral vascular diseases was 
examined. Similar to previous studies, it was found higher prevalence of diabetes mellitus, 
hypertension, dyslipidemia, and smoking in patients with psoriasis. After controlling for 
these variables, a higher prevalence not only of ischemic heart disease but also of 
cerebrovascular and peripheral vascular diseases in patients with psoriasis compared with 
controls. Psoriasis was also found to be an independent risk factor for mortality. Psoriasis is 
associated with atherosclerosis. This association applies to coronary artery, cerebrovascular, 
and peripheral vascular diseases and results in increased mortality (Prodanovich et al., 
2009). Patients with psoriasis (N = 4752) between 1999 and 2001 and patients without a 
diagnosis of psoriasis (N = 23,760) who were matched by age and sex to the patients with 
psoriasis were analyzed. Of the total sample, 70 patients (0.2%) had acute myocardial infarct 
(AMI) during the 5-year follow-up period: 22 (0.5% of the patients with psoriasis) from the 
study cohort and 48 (0.2%) from the comparison cohort. The hazard of AMI during the 5-
year follow-up period was 2.10 times greater for patients with psoriasis than for comparison 
patients (Lin et al., 2011).The event rates and rate ratios (RRs) of cardiovascular death, 
myocardial infarct (MI), coronary revascularization, stroke and a composite of MI, stroke 
and cardiovascular death were increased in patients with psoriasis. The RRs increased with 
disease severity and decreased with age of onset. The risk was similar in patients with 
severe skin affection alone and those with PsA (Ahlehoff et al., 2010). Patients with psoriasis 
have an increased prevalence of major cardiovascular (CV) risk factors and a clinically 
significant increased risk of myocardial infarction, stroke, and CV death that is independent 
of conventional risk factors (Gelfand et al., 2011). These epidemiological studies have led to 
the recognition that psoriasis may be a systemic inflammatory disorder (Davidovici et al., 
2010). Two recent studies have added to this previously summarized literature. First, 
Ahlehoff et al. (2010), in a nationwide Danish study of 34,371 people with mild psoriasis and 
2,621 with severe psoriasis, demonstrated independent risk ratios (RRs) for CV death of 1.14 
and 1.57 respectively, with the greatest increase in young people ages 18–50, RR 2.98, with 
severe disease. The authors also compared CV risks in patients with severe psoriasis with 
the risks in patients with diabetes mellitus and found comparable increases in major adverse 
CV events and CV deaths in these groups, demonstrating the clinical importance of the risk 
of CV disease attributable to psoriasis. Other recent studies have investigated the clinical 
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significance of CV risk in patients with severe psoriasis, demonstrating that these patients 
have about a 6-year reduction in life expectancy and that excess risk of CV death is the 
largest contributor to this premature mortality (Abuabara et al., 2010; Gelfand et al., 2011) 
4.2 Metabolic syndrome 
Psoriasis is associated with metabolic syndrome, cardiovascular disease, and osteoporosis 
and may be considered a systemic disease (Nijsten & Wakkee, 2009). The metabolic 
syndrome is the constellation of abdominal obesity, dyslipidemia, hypertension and insulin 
resistance. Presence of the metabolic syndrome significantly increases a patient's risk for 
cardiovascular disease, stroke and type II diabetes. Recent studies have found that psoriasis 
patients are at increased risk for metabolic syndrome as well as the individual components 
of metabolic syndrome, and the two diseases appear linked through a common mechanism 
of inflammation. Psoriasis treatments have been shown to reduce the risk of developing 
metabolic syndrome components and comorbidities (Alsufyani et al., 2010). The prevalence 
of obesity in psoriatic patients within the “Utah Psoriasis Initiative” (UPI) population was 
higher than that in the general Utah population. Obesity appears to be the consequence of 
psoriasis and not a risk factor for onset of disease. It was not observed an increased risk for 
PsA in patients with obesity; furthermore, obesity did not affect the response or adverse 
effects of topical corticosteroids, light based treatments, and systemic medications. The 
prevalence of smoking in the UPI population was higher than in the general Utah 
population and higher than in the non-psoriatic population. It was found a higher 
prevalence of smokers in the obese population within the UPI than in the obese population 
within the Utah population (Herron et al., 2005) 
5. Psoriasis treatments  
Psoriasis is an inflammatory skin disease with a chronic relapsing course. In about 20%–30% 
of psoriatic patients, disease severity requires systemic treatment, which carries a huge 
economic and management burden for the healthcare system. The decision to employ 
systemic treatment, reserved for severe or extensive forms, needs to be weighed carefully 
and is influenced by factors from the host. Traditional treatments like: photochemotherapy, 
cyclosporin A, methotrexate, and acitretin, should be evaluated for each specific clinical 
condition (Altomare et al., 2009). Psoriasis is important to the clinician because it is common 
and has treatment implications beyond the care of skin lesions. It is important to the 
physician-scientist because it serves as a model for studies of mechanisms of chronic 
inflammation. It is important to the clinical-trial investigator because it is increasingly a 
first-choice disease indication for proof-of-principle studies of new pathogenesis-based 
therapeutic strategies. In recent years, advances have been made in elucidating the 
molecular mechanisms of psoriasis. However, major issues remain unresolved, including 
the primary nature of the disease as an epithelial or immunologic disorder, the autoimmune 
cause of the inflammatory process, the relevance of cutaneous versus systemic factors, and 
the role of genetic versus environmental influences on disease initiation, progression, and 
response to therapy. (Nestle et al., 2009). Psoriasis may lead to disability and significant 
effects on patients' quality of life. A challenge in psoriasis management is to use an effective 
therapy early in the disease course in order to achieve a safe and well tolerated maintenance 
of remission with an improvement of both skin and joint manifestations. Recent advances in 
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knowledge of the pathogenesis of psoriasis helped develop targeted treatment options that 
may be effective and well tolerated over long periods of administration, thus improving the 
patient's quality of life. These biologic agents specifically target tumor necrosis factor- 
(infliximab, etanercept, and adalimumab) or T cells (efalizumab) (de Felice et al., 2009). 
Immune modulating therapies gain increasing importance in treatment of patients with 
autoimmune diseases such as psoriasis. None of the currently applied biologics achieves 
significant clinical improvement in all treated patients. In an open label study, 20 psoriasis 
patients were treated weekly with Alefacept over 12 wk. Transcription of the tolerance-
associated gene (TOAG-1) is significantly up-regulated whereas receptor for hyaluronic 
acid mediated migration (RHAMM) transcription is down-regulated in PBMCs of 
responding patients before clinical improvement. TOAG-1 is exclusively localized within 
mitochondria. Overexpression of TOAG-1 in murine T cells leads to increased 
susceptibility to apoptosis. Addition of Alefacept to stimulated human T cells in vitro 
resulted in reduced frequencies of activated CD137+ cells, increased TOAG-1 but reduced 
RHAMM expression. This was accompanied by reduced proliferation and enhanced 
apoptosis. Inhibition of proliferation was dependent on enhanced PDL1 expression of 
APCs. Thus, peripheral changes of TOAG-1 and RHAMM expression can be used to 
predict clinical response to Alefacept treatment in psoriasis patients. In the presence of 
APCs Alefacept can inhibit T cell activation and survival by increasing expression of 
TOAG-1 on T cells and PDL1 on APCs (Keeren et al., 2009). 
People with mild to moderate chronic plaque psoriasis after 3 months had no significant 
difference in the reduction PASI score between classic acupuncture vs. sham acupuncture 
(Jerner et al., 1997). Significantly more people (64%) having a thermal bath (bicarbonate, 
calcium, and magnesium rich water) had improvement in PASI score at 3 months compared 
with people (11%) having tap water bath  (Zumiani et al., 2000).  
All the data from here on have been referenced in a deep analysis of treatments for psoriasis 
performed in an excellent review by Naldi & Rzany, 2009, a summary follows: Fish oil and 
effects of psychotherapy reported inconclusive results with chronic plaque psoriasis. 
Tazarotene, a topical retinoid, may be more effective in the short term (6–12 weeks) at 
improving symptoms of mild to moderate chronic plaque psoriasis. Vitamin D derivatives 
(topical) were more effective at improving psoriasis severity scores at 3–8 weeks. Different 
types of vitamin D derivatives compared with each other revealed Calcipotriol may be more 
effective than tacalcitol and calcitriol at reducing psoriasis severity scores at 8 weeks. 
Calcipotriol may be more effective at prolonging time to relapse in people with stable 
psoriasis for at least 3 months after prior treatment with methotrexate for 6 months. 
Dithranol may be more effective at improving psoriasis severity scores at 4–8 weeks. 
Emollients plus UVB radiation compared with UVB alone and oil-in-water emollient plus 
UVB radiation may temporarily be more effective at improving psoriasis at 12 weeks. There 
is consensus that they are effective, and are mostly used initially or as adjunctive treatment 
in people with chronic plaque psoriasis. Salicylic acid may be no more effective at 
improving psoriasis severity scores at 3 weeks. There is consensus that keratolytics are a 
useful adjunct to other treatments for psoriasis Topical corticosteroids applied less 
frequently may be more effective at maintaining clear or nearly cleared areas at 6 months 
but they may cause striae and atrophy, which increase with potency and use of occlusive 
dressings. Continuous use may lead to adrenocortical suppression, and case reports suggest 
www.intechopen.com
 Psoriasis – A Systemic Disease 
 
16
that severe flares of the disease may occur on withdrawal. Coal tar plus fatty acids is no 
more effective at 8 weeks at improving composite scores for erythema, desquamation, and 
infiltration in people with mild to moderate chronic plaque psoriasis. Goeckerman 
treatment compared with UVB irradiation alone. Goeckerman treatment (daily application 
of coal tar followed by UVB irradiation) may be no more effective at improving response 
rates in people with chronic plaque psoriasis. Compared with no intervention Heliotherapy 
may be more effective at improving symptom severity scores at 1 year in people with all 
forms of chronic plaque psoriasis severities. There is consensus that heliotherapy is an 
effective option for most people with chronic plaque psoriasis. Different doses of psoralen in 
PUVA regimens compared with each other. Higher doses of psoralen are more effective at 
increasing clearance of lesions in people with severe psoriasis. Maintenance treatment with 
PUVA is more effective at reducing relapses at 18 months in people whose psoriasis has 
been cleared with prior PUVA treatment. Long-term adverse effects of PUVA treatment 
include photoaging and skin cancer, mainly squamous cell carcinoma. Narrowband UVB 
and broadband UVB may be equally effective at increasing clearance rates. Twice-weekly 
and three times-weekly administration of ultraviolet light are equally effective at increasing 
clearance rates, but twice-weekly treatment prolongs the time to reach clearance in people 
with mild to moderate psoriasis. Compared with placebo UVA sun bed treatment may be 
more effective than visible light at improving psoriasis severity scores in people with mild 
to moderate chronic stable plaque psoriasis. Alefacept is more effective at increasing the 
proportion of people with a reduction in psoriasis severity scores at 12 weeks. The FDA 
issued a Medical Product Safety Alert to inform people that alefacept reduces CD4+ T 
lymphocyte counts and should not be given to people with HIV. Efalizumab is more 
effective at increasing the proportion of people who achieve an improvement in psoriasis 
severity scores at 12 weeks in moderate to severe psoriasis. The FDA issued a warning about 
Raptiva (efalizumab) to healthcare professionals and patients about reports of immune 
mediated haemolytic anaemia, and warnings regarding post-marketing reports of 
thrombocytopenia and serious infections including necrotising fasciitis, tuberculous 
pneumonia, bacterial sepsis with seeding of distant sites, severe pneumonia with 
neutropenia, and worsening of infection (e.g. cellulitis, pneumonia) despite antimicrobial 
treatment. Raptiva (efalizumab) has a potential risk of developing progressive multifocal 
leukoencephalopathy. Efalizumab is a humanised monoclonal antibody which targets the 
CD11a component of lymphocyte function-associated antigen-1. It is a relatively new drug 
for the treatment of psoriasis. Efalizumab has been associated in some cases with fatal brain 
infections and has been withdrawn from the market (Major, 2010). Etanercept is more 
effective at increasing the proportion of people with improved psoriasis severity scores at 
12–24 weeks in people with moderate to severe psoriasis. A drug safety alert has been 
issued on the risk of opportunistic fungal infections of lymphoma and other malignancies in 
children and adolescents associated with TNF- blockers, which could be fatal. Etanercept is 
a recombinant molecule consisting of the human TNF- p75 receptor fused to the Fc portion 
of the human immunoglobulin G1 molecule.  
Infliximab is more effective at increasing the proportion of people who achieve an 
improvement in psoriasis severity scores at 10 weeks in people with moderate to severe 
psoriasis. A drug safety alert has been issued on the risk of opportunistic fungal infection of 
lymphoma and other malignancies in children and adolescents, and the risks of leukaemia 
and new onset psoriasis. Infliximab is a monoclonal antibody that binds to and inhibits the 
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activity of TNF- Compared with placebo Adalimumab is more effective at increasing the 
proportion of people with moderate to severe psoriasis who achieve an improvement in 
severity scores at 12 weeks. Drug safety alerts have been issued on the risk of hepatosplenic 
T-cell lymphoma associated with adalimumab and the risk of opportunistic fungal 
infections associated with TNF- which could be fatal. A drug safety alert has been issued 
on the increased risk of lymphoma and other malignancies in children and adolescents, and 
the risks of leukaemia and new onset psoriasis, associated with TNF- blockers. Ciclosporin 
may be more effective at 10 weeks at increasing lesion clearance and at reducing psoriasis 
severity scores in people with severe psoriasis. Conventional oil-based ciclosporin and 
microemulsion preconcentrate are equally effective at increasing the proportion of people 
achieving a marked response. Ciclosporin is more effective at increasing the proportion of 
people who remain in remission. Ciclosporin has been associated with hypertension, renal 
dysfunction and increased risk of malignancies for up to 5 years. Ciclosporin is an 
established treatment option for moderate to severe psoriasis. Relapses are often seen on 
withdrawal, and long-term treatment is limited by adverse effects. Dimethylfumaric acid 
alone or mixed with monoethyl fumaric acid may be more effective at 16 weeks at reducing 
psoriasis severity scores in people with severe psoriasis. Oral fumaric acid plus calcipotriol 
may be more effective at improving psoriasis scores at 13 weeks in people with severe 
chronic plaque psoriasis. Fumaric acid esters have been associated with flushing and with 
gastrointestinal symptoms.  
Methotrexate may be more effective at reducing the surface area of psoriasis at 12 weeks in 
people with psoriatic arthritis, but has been associated with acute myelosuppression. Long-
term methotrexate carries the risk of hepatic fibrosis and cirrhosis, which is related to the 
dose regimen employed. People using methotrexate are closely monitored for liver toxicity 
and are advised to limit their consumption of alcohol. The most reliable test of liver damage 
remains needle biopsy of the liver. When treatment was stopped, 45% of people experienced 
a full relapse within 6 months. Acitretin and etretinate are equally effective at increasing the 
proportion of people who achieve a marked improvement as measured by a reduction in 
psoriasis severity scores. Teratogenicity renders oral retinoids less acceptable. Etretinate is 
no longer available in many countries. Leflunomide may be more effective in people with 
psoriatic arthritis at increasing the proportion of people with a reduction in psoriasis 
symptom severity scores at 24 weeks. Leflunomide significantly increased the proportion of 
people with at least a 75% improvement in PASI but had diarrhoea (24% with leflunomide 
vs. 13% with placebo). More people taking leflunomide had increased liver enzymes and 
tiredness lethargy (alanine transaminase increase of at least 2 times the upper limit of 
normal:12% with leflunomide v 5% with placebo; tiredness/lethargy: 6% with leflunomide 
vs. 1% with placebo). Pimecrolimus significantly improved PASI at 12 weeks, but with 
higher rates of gastrointestinal disorders, pruritus, and paraesthesia in the pimecrolimus 
groups compared with the placebo group (Naldi & Rzany, 2009). 
5.1 Treatment with drug product Leismania amastigotes vaccine 
While treating subjects in Venezuela with a vaccine containing Leishmania amastigotes 
antigens for prevention of cutaneous leishmaniasis (CL), (O’Daly et al., 1995a, 1995b) we 
observed 100% clinical remission of a psoriatic lesion in one subject, a natural double blind 
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serendipity finding. A first generation polyvalent vaccine (AS100-1) was manufactured with 
protein from four cultured Leishmania species: L(L)amazonensis, L(V)brasiliensis, L(L)chagasi 
and  L(L)venezuelensis (O’Daly et al., 2009a). 
5.2 Characterization of the amastigotes drug product 
Protein test samples from the amastigote extracts of the four Leishmania spp. present in 
AS100-1 were tested for the presence of Leishmania DNA. PCR reactions for amplification of 
the variable regions of kDNA minicircles of Leishmania were performed to confirm the 
absence or presence of parasite DNA in the polyvalent AS100-1 final drug product. DNA 
isolated from Leishmania amastigote parasites were used as positive controls. No PCR 
product was detected in the AS100-1 protein samples. As expected, agarose gel 
electrophoresis of the 610 and 116pb fragments showed presence of DNA in the positive 
controls. Additional PCR sequencing from the positive controls showed 92% identity with 
the kinetoplast DNA minicircles. Lipophosphoglycan (LPG) is a glycoconjugate present on 
metacyclic promastigotes, which functions as a virulence factor in all Leishmania spp. The 
final product of amastigotes extracts after TLCK treatment and NP40 surface antigen 
extraction, had 10 ng/m or less of LPG. The acceptable endotoxin limit for the drug 
substance was 700 EU/ml. A sample of the drug substance was screened for endotoxin 
content with results <50 EU/ml but >25 EU/ml. well below the acceptable limit. BSA was 
between 12.5 and 25.0 ng/ml, evidence that no fetal bovine serum (FBS) proteins from the 
culture medium were present. SDS acrylamide gels of AS100-1 drug product under 
reducing conditions exhibited 23–30 bands from 112.0 to 10.0 kDa molecular weight in the 
four Leishmania spp.; 21 bands (70%) with similar molecular weights (value variations 1% or 
less) in all lots. The percent homology between lots of the same specie was L(L)amazonensis 
96.6%; L(V)brasiliensis 86.7%; L(L)chagasi 95.8%; L(L)venezuelensis 91.3% (O’Daly et al., 2009a). 
5.3 Clinical trial with amastigote antigens vaccine 
A double-blind, placebo-controlled, parallel group study, of multiple doses of AS100-1 was 
performed on psoriatic subjects, to confirm safety and efficacy. Treatment of plaque 
psoriasis, was conducted in 2,770 volunteers and included plaque (79%), guttate (10%), 
plaque and guttate (10%), palm/plantar (0.3%), erythrodermia (1.8%), inverse (0.8%), plaque 
and arthritis (3.4%) and nail psoriasis (0.3%). Eficacy of AS100-1 was assessed by performing 
skin examinations and recording psoriasis area and severity index (PASI) parameters at each 
visit. The primary eficacy parameters were the percentage reduction in PASI score at each 
visit and the comparative proportions of subjects with 100, 75 and 50% PASI improvement 
in each treatment group. The lesions and the extent of body surface area involved were 
measured separately for the head (Ah), trunk (At), upper extremities (Au) and lower 
extremities (Al). The PASI combines lesion measurements of the skin erythema, (E, redness), 
skin induration (I, thickness) and skin desquamation (D, scaliness) of the lesions. Each sign 
in the lesion was quantified as follows: 0 none, 1 slight, 2 mild, 3 moderate and 4 severe. The 
extent of body surface area affected was evaluated as follows: 1 < 10%, 2 = 10–30%, 3 = 30–
50%, 4 = 50–70%, 5 = 70–90%, 6 > 90%. For evaluation purposes, the weighted contribution 
of each section of the body to the total body surface area is as follows, the head 10%, the 
thorax 30%, the upper extremities 20% and the lower extremities 40%. To calculate disease 
severity, the following formula was applied: PASI = 0.1(Eh + Ih + Dh)Ah + 0.3(Et + It + 
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Dt)At +0.2(Eu + Iu + Du)Au + 0.4(El + Il + Dl)Al. PASI scores rise or fall in units of tenths 
(0.1) and range from 0.0 to 72.0. A score of 0.0 indicates absence of lesions, while a score of 
72.0 represents the malignant form of the disease (erythrodermia). Body surface area 
involvement of over 10% or a PASI score greater than 10.0–12.0 is used as a criterion for 
severe disease. Percent PASI reduction was calculated as follows: (PASI at base line—PASI 
at each visit)/PASI at baseline* 100. Baseline PASI compared with post-treatment values 
were: PASI 100, 23%; PASI 75, 45%; PASI 50, 13%; PASI 10, 9%; <PASI 10, 3% while 7% quit 
treatment. Of the 648 subjects (23%) who experienced total remission of lesions, 188 (29%) 
had relapses of their disease after 15.4 months. The PASI values at the time of the first 
relapse were 7.7 units, one-third of the PASI value (21.0 units) recorded before any 
treatment. The new remission occurred with 7.1 doses of AS100 after 5.8 weeks, a shorter 
time period than initially observed in the first treatment cycle for clinical remission of 
lesions. In the relapsing group, 161 of the 188 subjects (85.6%) experienced new remission of 
lesions after six to seven doses of AS100 (O’Daly et al., 2009a). 
There were no serious adverse events attributed to the treatment drug. Some patients with 
PsA benefited after treatment (see below). Of the 2,770 subjects treated in the open label 
psoriasis study, a random group of 108 subjects was selected for antibody screening. The 
test group included a positive control group with active CL, a negative control group before 
treatment and subgroups with one to six doses of the immunotherapeutic agent. All subjects 
received 500 µg/dose of AS100-1. The concurrent negative control group (n = 36) consisted 
of psoriatic subjects, prior to any AS100-1 treatment, with no previous history of Leishmania 
infection, no prior exposure to AS100-1 and with a negative delayed type hypersensitivity 
(DTH) to Leishmania antigens. All subgroups with one to six doses of AS100-1 in the 
treatment group had the same results as the negative control group, exhibiting antibody 
values between 30 and 87 ng/ml; well below 100 ng/ml, the cutoff value to consider a 
reaction as positive. It is also interesting to note that after four doses of AS100-1, all subjects 
had undetectable levels of antibodies (ELISA), but a positive DTH cellular response to AS100-1 
after intradermic reaction (IDR) ≥10 mm  in diameter with Leishmania antigens. These results 
suggest that the AS100-1 drug product does not induce significant humoral immunity but a 
strong cellular immunity. Approximately 2,289 subjects (83%) experienced at least one adverse 
event (AE). The most frequent AE were injection site related, and included the following, pain 
43%, nodule formation 23%, heat 21% and erythema 14%. The injection sites were assessed 
after each administration of the study drug. Injection site related AE, were relatively short 
lived, lasting between 24 to 72 h. The types of systemic AE and their rates of occurrence were 
as follows: fever 18%, general discomfort 12%, a flulike syndrome 11%, pruritus 8%, sleepiness 
8%, accidental injury 8%, cough 6%, dizziness 6%. AE attributed to the treatment drug were 
rated mild or moderate in severity, with none being classified as serious. The few severe 
adverse events that occurred were attributed to other diseases, the subjects were experiencing 
while participating in the study trial. There were no age or gender diferences observed for AE, 
and no deaths occurred during the study. All adverse events resolved without intervention, 
usually within 24–72 h. (O’Daly et al., 2009a). 
To determine the effective factor, a single blind trial with four monovalent second 
generation vaccines (AS100-2) was performed. The AS100-2 trial was a single blind AS100-1 
controlled trial with four treatment groups one for each AS1002 vaccine (AS1002-
amazonensis, AS1002-brasiliensis, AS1002-chagasi, and AS1002-venezuelensis). The trial 
included 26 subjects, 58% females, average 43.8±16.4 years old, and age range 8–76 years, 
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initial PASI 10.2± 6.6 units, time with psoriasis 12.2±13.1 years. The treatment subjects 
received 500 µg/ dose injections of AS100-2 and control subjects received 500 µg/dose of 
AS100-1. The results achieved with monovalent AS100-2 produced reductions in psoriatic 
lesions similar to those induced by polyvalent AS100-1. AS100-2 vaccines were further 
purified, resulting in seven chromatography fractions (AS200) per species. AS100-2, and 
AS200 final product, gave the following results for LPG and endotoxin: LPG: 10 ng/ml or 
less; Endotoxin: <50 EU/ml but >25 EU/ml. Parasitic DNA was absent in all products and 
BSA was between 12.5 and 25.0 ng/ml, basically within the same range, as previously 
published AS100-1 values. No carbohydrates were found in AS100-1, AS100-2 or Lb 
fractions by HPLC analysis or staining of gels with PAS-SCHIFF (O’Daly et al., 2009b). 
Subsequently, a single-blind trial in 55 subjects treated with a third generation vaccine 
AS200 prepared with seven DEAE chromatography fractions from L(V)brasiliensis was 
performed. The AS200 study was a single-blind, AS100-1 controlled trial, with a seven arm 
treatment group, one for each AS200 (Lb) vaccine. The AS200 trial included 53 subjects, 62% 
females average 40.6±18.6 years old, age range 7–78 years of age, initial PASI 26.4±19.2, time 
with psoriasis 15.0±12 years.The treatment subjects received four 200 µg/dose injections of 
AS200 (Lb) and control subjects received four 500 µg/dose of AS100-1. However, treatment 
with the vaccine containing fraction 7 was discontinued due to general discomfort and 
psoriasis flare subsequent to vaccination in one subject. All subjects had PASI scores 
determined prior to treatment, prior to each injection, and at follow-up for 2 weeks after the 
last injection. All AS200 (Lb) vaccines induced PASI reductions in the same range as the active 
control. Protein (DEAE) fractions 2, 3, 4, and 5 had similar values and induced the highest in 
vitro lymphocyte stimulation index (SI) values in peripheral blood mononuclear cells (PBMC) 
from post-treatment PASI100% reduction subjects, with no statistical differences among them. 
The same fractions, from L(V)brsiliensis and L(L)chagasi species, also yielded the highest IDR 
diameter in DTH screenings. All leishmania DEAE fractions stimulated lymphocytes from 
PBMC from patients in vitro, after vaccination wit AS100-1, none were immunosuppressors, 
contrary to all treatment in the market today (O’Daly et al., 2009b).  
Long-term heat shock proteins (Hsp) confrontation of the immune system similar in the host 
and invaders may convert the immune response against these host antigens and promote 
and/or decrease autoimmune diseases including psoriasis (Boyman et al., 2005; Rajesh 
Rajaiah & Moudgil, 2009; Rambukkana et al., 1993). There is evidence that recognition of 
self-Hsp60 can have beneficial effects in arthritis and may offer new strategies for improved 
control measures in the inflammatory processes by administration of peptides cross-reactive 
to self-determinants (Zügel & Kaufmann, 1999). Hsp60, Hsp70, Gp96 function as host-
derived ligands for toll like receptors (TLR2), and have been described to play a role in the 
pathogenesis of RA and psoriasis (Rajesh Rajaiah & Moudgil 2009). Leishmania antigens are 
produced after a heat shock in promastigotes that become amastigotes in a liquid culture 
medium (O’Daly & Rodríguez, 1988). The molecular weight of AS200 is similar to the range 
of most Hsp host ligands (50–70 kDa) and could be inhibiting the symptoms of psoriasis, 
psoriatic arthritis and CIA by competing with peptides in the respective receptors (O’Daly et 
al., 2009a, 2009b, 2010a, 2011). 
Two male subjects, both HIV+; 36 and 41 years of age, with plaque psoriasis for 4 years in 
one subject and 7 months in the other were treated with AS100-1. Both subjects had no 
familial history of psoriasis, and were treated with AS100-1 concurrently with their 
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previously prescribed retroviral treatments. The AS100-1 treatment consisted of 500 
µg/dose, injected in the deltoid area, every 2 weeks. Baseline PASI for one subject was 26.4 
units, while the other subject presented with a baseline PASI of 32.4 units. Both subjects 
showed clinical remission of psoriasis after treatment with AS100-1. The hematologic values 
with respect to total lymphocytes (CD3, CD4, and CD8 cells) were lower than the values 
routinely found in healthy subjects. One subject had a relapse after the ninth dose and 
subsequently received a second course of treatment 3 weeks later. The second course 
resulted in clinical remission of the psoriatic lesions. Neither of these two subjects presented 
local adverse events nor did they present any systemic adverse events after vaccination 
(O’Daly et al., 2009b). 
5.4 Cellular immunity in guinea pigs and regression of lesions in experimental 
Rheumatoid Arthritis model with amastigote antigens vaccine 
AS200 Leishmania antigenic fractions induced linear DTH reactions in guinea pigs over a 1-
40 µg dose range. This finding allowed us to build a potency assay for the drug product. 
Interestingly, RA, another autoimmune disease, shares several similarities with psoriasis 
and PsA. While some diseases lack acceptable animal models for adequate study, this is not 
the case with RA. Collagen induced arthritis (CIA) is an experimental animal model that has 
been used to dissect the pathogenesis of human RA. The model is dependent on activated T 
cells, is associated with both cell mediated and humoral immunity to collagen and can be 
induced upon immunization with heterologous collagen II (CII) or by monoclonal 
antibodies to CII combined with LPS in DBA/1 mice. When a DBA-1 mouse CIA model was 
used to compare AS200 treatment against: a polyvalent vaccine (AS100-1), a monovalent 
vaccine (AS100-2) and placebo, the AS200 treated mice had the least amount of forepaw 
inflammation and the lowest mean arthritis scores (O’Daly et al., 2010a). 
5.5 Lympocyte subsets in peripheral blood monocuclear cells of psoriatic patients, 
before and after treatment with amastigote polyvalent vaccine 
Peripheral blood mononuclear cells (PBMC) collected from subjects prior to treatment and 
post-treatment with AS100-1 were analyzed by flow cytometry. Lymphocyte subsets (LS) 
varied with PASI range (1-10, 11-20 and 21-72). Pretreatment absolute values of gated LS 
were as follows: CD4+CD8-, CD3+CD8-, CD8+CD3+, CD8+CD4- and CD8+HLA- decreased 
in PBMC as PASI increased, suggesting migration from the blood to the skin. Contrary to 
the previous finding, the following LS, CD8+HLA+, HLA+CD8-, CD8+CD4+, CD19, and 
membrane surface immunoglobulin IgA+, IgD+ and IgM+ increased in PBMC as PASI 
increased, suggesting activation and proliferation by unknown antigens in the skin 
lesions. After treatment with seven doses of AS100-1, the following LS, CD3+CD8-, 
CD8+CD3-, HLA+CD8-, CD8+HLA+ and CD4+CD8-, increased as PASI returns to normal 
values and psoriatic plaques disappeared, while CD8+CD3+, CD8+HLA-, CD19 and 
CD8+CD4+ decreased in PBMC suggesting lower sensitization in skin. Lymphocyte 
trafficking from blood to skin decreased significantly, stopping the vicious cycle as 
psoriasis lesions disappeared (O’Daly et al., 2010b). Previously we demonstrated that 
leishmania antigens induced T cell proliferation and absence of immunosuppression after 
stimulating PBMC from psoriatic patients with amastigote fractions. DTH positive 
reactions were found with isolated amastigote antigens in humans in vivo, after treatment 
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with AS100-1 polyvalent vaccine. These facts of in vivo and in vitro T cells stimulation 
(O’Daly et al., 2009b) suggest that variations in blood LS, before and after treatment in 
psoriatic subjects, is a function of lymphocyte trafficking from blood to skin and vice 
versa, as well as T cell activation in skin plaques, not to killing of T cells as has been 
described with current treatments used in psoriatic patients. 
6. Psoriatic arthritis 
The first description of PsA is attributed to Louis Aliberti, who in 1818 first noted the 
relationship between psoriasis and arthritis (O’Neill & Silman, 1994). Pierre Bazin then 
described “Psoriasis Arthritique” in 1860, followed by Charles Bourdillon in 1888 with 
“Psoriasis et Arthropathies”. Jeghers and Robinson in 1937, and Vilanova and Piñol in 1951 
described PsA as a unique entity   (Vilanova & Pinol, 1951). All studies of PsA use the 
criteria by Moll and Wright in their classic paper published in 1973 (Moll & Wright, 1973) 
summarized as follows: A- presence of psoriasis, B- inflammatory arthritis and C- negative 
test for rheumatoid factor. The PsA subgroups described with these criteria were:  1- Distal 
interphalangeal (DIP) joint disease (5%); 2- Asymmetrical oligoarthritis (70%); 3- 
Polyarthritis (15%); 4- Spondylitis (5%); 5- Arthritis mutilans (5%), (Wright 1956, 1959a, 
1959b). Gladman expanded the five sub-groups to seven: Distal disease (DIP only affected), 
oligoarthritis (<4 joints), polyarthritis, spondylitis only, distal disease plus spondylitis, 
oligoarthritis plus spondylitis and polyarthritis plus spondylitis (Gladman et al., 1987). 
6.1 Psoriasis artritis epidemiology   
Psoriasis is widely diffused in the World. Its average prevalence is about 3-4%. This is 
probably an underestimate, for it is mostly based on self-reports. In fact, on the one hand 
minimal psoriasis, e.g. nail disease, could remain undiagnosed; on the other, precise 
classification criteria for PsA are lacking and the skin disease is often of elusive nature. The 
frequency of PsA may be higher than commonly believed, as suggested by recent studies 
reporting a prevalence of up to 0.42%. There are no major differences in the frequency of 
psoriasis between sexes, or specific time trends (Cimmino, 2007). Prevalence of PsA varies 
from 5-40% in several trials. A large study conducted in the UK, Italy, France, Spain and 
Germany in 2006 found 8.1% prevalence of PsA in patients with psoriasis. Survival analysis 
indicated that the incidence of PsA among plaque psoriasis patients remained constant at 74 
per 100 person-years, while the prevalence increased with time since diagnosis of psoriasis, 
reaching 20.5% after 30 years (Christophers et al., 2010). A population based study in 
Minnesota USA, reported the annual incidence of PsA per 100,000 to be 7.2. The incidence 
increased from 3.6 between 1970 and 1979, to 9.8 between 1990 and 2000, providing the first 
evidence that the incidence of psoriasis increased during recent decades (Wilson et al., 2009). 
A previous study from 1982-1992 in the same community revealed an incidence rate of 
6.59% per 100,000 US population (Shbeeb et al., 2000). The prevalence and incidence 
estimates of psoriasis and PsA show ethnic and geographic variations, being generally more 
common in the colder north than in the tropics. In Europe the prevalence of psoriasis varies 
anywhere from 0.6 to 6.5%. In the USA, the prevalence of diagnosed psoriasis is 3.15%. The 
prevalence in Africa varies depending on geographic location, being lowest in West Africa. 
Psoriasis is less prevalent in China (Chang et al., 2009), and Japan than in Europe, and has 
not been described in natives of the Andean region of South America (Kim et al., 2010; 
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Gottlieb et al., 2008). The prevalence of PsA also shows similar variation, being highest in 
people of European descent and lowest in the Japanese. Although, study methodology and 
case definition may explain some of the variations, genetic and environmental factors are 
important (Lotti et al., 2010).     
People with psoriasis were identified from the computerized morbidity indices of 2 large 
UK general practices, total population 22,500. Questionnaires were mailed to all 633 patients 
thus identified. Of the respondents, a 50% sample was assessed clinically and a proportion 
had blood samples and radiographs taken. Of these 93 people, 12 were thought to have PsA 
clinically, all fulfilling the CASPAR criteria for PsA. Six of the 93 examined patients did not 
have psoriasis or a family history of psoriasis and had no historical features or clinical signs 
of psoriasis on interview and examination. The estimated prevalence of PsA in this 
population, using the CASPAR criteria, was 13.8% (Ibrahim et al., 2009). Many challenges 
have made it difficult to determine the prevalence of spondyloarthritis (SpA) in North 
America. They include the ethnic heterogeneity of the population, the lack of feasibility of 
applying current criteria as human leukocyte antigen-B27 testing and pelvic radiographs 
and magnetic resonance imaging scanning, and the transient nature of some SpA symptoms 
like peripheral arthritis and enthesitis. Current estimates of the prevalence of SpA in the 
United States range between 0.2% and 0.5% for ankylosing spondylitis, 0.1% for psoriatic 
arthritis, 0.065% for enteropathic peripheral arthritis,   between 0.05% and 0.25% for 
enteropathic axial arthritis and an overall prevalence of SpA as high as >1% (Reveille, 2011). 
A population-based study was conducted in two regions of the Czech Republic (with a total 
population of 186,000 inhabitants), on condition of confirming a definite diagnosis according 
to existing classification criteria during the study period (1 March 2002 to 1 March 2003). 
The age-standardized estimates of incidence and prevalence were calculated using the 
European standard population. The total annual incidence of PsA in adults aged ≥ 16 years 
was 3.6/100000 and the prevalence of PsA was 49.1/100000. The annual incidence of 
ankylosing spondylitis (AS) in adults was 6.4/100000 and the prevalence of AS was 
94.2/100000. The annual incidence of reactive arthritis (ReA) in adults was 9.3/100000 and 
the prevalence of ReA was 91.3/100000. The annual incidence and prevalence rates of PsA, 
AS, and ReA compared well with data reported from other countries (Hanova et al., 2010). 
SpA includes a group of diseases that share immunogenetic, clinical and radiologic findings, 
with a particular involvement of the axial skeleton and the entheses. SpA patients attending 
ambulatory care in 11 rheumatology services located in 6 Argentine provinces were 
included in a prospective, observational multicentre cohort of SpA. A total of 402 patients 
were included; 59% were male, with median age of 48.3 years and median disease duration 
of 8 years. Eighty-six patients were diagnosed with AS, 242 with PsA, 25 with ReA, 10 with 
SpA associated with inflammatory bowel disease, 33 with undifferentiated SpA and 6 with 
juvenile AS (Buschiazzo et al., 2011). A cohort of 233 SpA patients, observed in 2 centers in 
Guatemala City, Guatemala, and in hospitals in San Salvador, El Salvador, and San José, 
Costa Rica was analyzed. Guatemalan patients were either from the clinic of Guatemalan 
Association against Rheumatic Diseases (n = 105) or from the private clinic of AGK (n = 78). 
El Salvador patients (n = 17) were from Hospital Instituto Salvadoreño del Seguro Social, 
and Costa Rican patients (n = 33) were from Hospital Calderón Guardia, San José, Costa 
Rica. Except for the Costa Rican data, which were published in 2007, the patients' medical 
records were analyzed using standardized questionnaires. Prevalence of SpA was slightly 
higher in females than males (57% versus 43%, respectively). The median age was 47.5 years. 
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Most of the patients were diagnosed with ReA or undifferentiated arthritis (47% and 33%, 
respectively); 10% of patients had AS and 9% PsA (García-Kutzbach et al., 2011).        
During the period of 2006 to 2007, Twenty eight university centers in Brazil used a 
standardized protocol of investigation to study the epidemiological, clinical and radiological 
variables of 1036 consecutive patients with the diagnosis of SpA. Validated translated 
(Portuguese) versions of the Bath Ankylosing Spondylitis (AS) Disease Activity Index and 
the Bath AS Functional Index were applied. Patient diagnoses were predominantly AS 
(72.3%), followed by PsA (13.7%), undifferentiated SpA (6.3%), ReA (3.6%), juvenile SpA 
(3.1%) and arthritis related to inflammatory bowel disease (1.0%). There was a 
predominance of male (73.6%) and white (59.5%) patients. Pure axial disease was observed 
in 36.7% of the patients, whereas the mixed pattern (axial, peripheral and entheseal) was 
observed in 47.9%. The most common extra-articular involvement was anterior uveitis 
(20.2%). HLA-B27 was positive in 69.5% of the tested patients (Sampaio-Barros, 2011). The 
mortality in a cohort of 453 patients with PsA (232 men, 221 women) was analyzed. The 
sudden mortality rate (SMR) for the men was 67.87%, and for the women, 97.01% and the 
overall SMR for the PsA cohort was 81.82%.The leading causes of death in this cohort were 
cardiovascular disease (38%), diseases of the respiratory system (27%), and malignancy 
(14%).These results suggest that mortality in the single center PsA cohort is not significantly 
different from the general UK population (Buckley et al., 2010).  
A wide variation on the incidence and prevalence of PsA has been reported in different 
countries. The prevalence in China was similar to the rest of the world, whereas the 
incidence and prevalence of PsA was much lower in Japan. Among patients with psoriasis, 
6-42% of the Caucasians were reported to have PsA, but figures were lower from Asian 
countries (1-9%). Divergent distribution of HLA in different ethnic groups and other genetic 
determinants may account for these differences in prevalence. PsA affects men and women 
almost equally in Chinese, Japanese and Iranians, which is similar to their Caucasian 
counterparts. Polyarthritis developing in the fourth decade was the commonest pattern of 
arthritis among Chinese, Indians, Iranians, Kuwaiti Arabs and Malays. Arthritis mutilans 
and eye lesions have rarely been reported in Asian countries. Chinese patients with nail 
disease and DIP joints involvement have a significantly higher risk of developing deformed 
joints. Premature atherosclerosis has been recognized as an important comorbidity in Asian 
patients with PsA. Increased prevalence of traditional cardiovascular risk factors associated 
with PsA suggested that the two conditions may share the same inflammatory pathway. 
Carotid intima-media thickness can identify PsA patients with subclinical atherosclerosis 
who may benefit from early intervention (Tam et al., 2009) 
6.2 Psoriatic arthritis in the clinic  
Psoriatic systemic disease encompassing skin, joint and nail involvement is an autoimmune 
process as evidenced from animal models, the HLA-Cw6 association in man, T cells 
infiltration in lesional skin and the response to T cell targeted therapies. The nails and joints 
are associated with inflammation at points of ligament or tendon insertion (i.e., enthesitis). It 
has been postulated that response to tissue stressing of the integrated nail-joint apparatus, 
rather than autoimmunity, is driving the inflammatory process with a relative differential 
involvement of adaptive and innate immunity in the psoriatic disease (McGonagle et al., 
2010). Nail fold psoriasis and DIP joint arthritis were associated with nail involvement and 
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were common in PsA patients. Nail psoriasis has been postulated to be related to the 
Koebner phenomenon and local inflammatory DIP joint arthritis, and probably indicative of 
distal phalanx enthesitis in PsA patients (Maejima et al., 2010).  
PsA is classified as a SpA and characterized by synovitis, enthesitis, dactylitis, and 
spondylitis, usually manifesting in a person with skin and nail psoriasis. Our understanding 
about the PsA disease state, its genetics, pathophysiology, and comorbidities, as well as our 
ability to assess and treat the disease, has advanced as a result of significant collaborative 
efforts by rheumatologists and dermatologists (Mease, 2010a). For many years the concept 
of PsA as a separate disease entity was controversial, its importance has been 
underestimated. Dermatologists focus on psoriatic skin may overlook PsA due to its clinical 
heterogeneity or when only minor symptoms are present such as mild enthesitis or arthritis 
of DIP joints. Because skin lesions occur years before the manifestation of arthritis, however, 
it is likely that many patients are being seen by a dermatologist when PsA initially develops. 
A study among 1511 patients found 20% had PsA; in 85% of the cases, PsA was newly 
diagnosed. Of these patients more than 95% had active arthritis and 53% had five or more 
joints affected. Polyarthritis (58%) was the most common manifestation pattern, followed by 
oligoarthritis (31%) and arthritis mutilans (4%). DIP involvement was present in 41% and 
dactylitis in 23% of the patients. Compared with patients without arthritis, patients with 
PsA had more severe skin symptoms (mean PASI 14.3 vs. 11.5), a lower quality of life and 
greater impairment of productivity parameters (Reich et al., 2009). The Classification of 
Psoriatic Arthritis (CASPAR) study group was established for classification criteria for PsA. 
The CASPAR criteria comprised: 1- Evidence of psoriasis (a) Current psoriatic skin or scalp 
disease present today as judged by a rheumatologist or dermatologist (b) Personal history of 
psoriasis that may be obtained from patient (c) Family history of psoriasis in a first or 
second degree relative according to patient report, family doctor, dermatologist, 
rheumatologist or other qualified health-care provider. 2- Psoriatic nail dystrophy including 
onycholysis, pitting and hyperkeratosis observed on current physical examination. 3- A 
negative test for rheumatoid factor by any method except latex but preferably by ELISA or 
nephelometry. 4- Dactylitis: a) current swelling of an entire digit b) history of dactylitis 
recorded by a rheumatologist. 5- Radiological evidence of juxta-articular new bone 
formation as ill-defined ossification near joint margins (but excluding osteophyte formation) 
on plain X-rays of hand or foot. Using the CASPAR criteria, the combination of psoriasis 
and inflammatory arthritis gave 0.96 for sensitivity and 0.97 for specificity, respectively 
(Taylor et al., 2006; Chandran et al., 2007; Coates & Helliwell, 2008). The Toronto group 
evaluated the use of the CASPAR criteria in early disease and found a sensitivity of 99.1% in 
those patients with disease duration of less than 2.5 years and a sensitivity of 100% for those 
with disease duration of less than 12 months (Chandran et al., 2007). Both dactylitis and 
enthesitis are hallmark features of PsA, and dactylitis is a severity marker for the disease. 
Spinal disease in PsA is qualitatively and quantitatively different from classical AS, and a 
new scoring system combines elements of the “Bath Ankylosing Spondylitis Radiology 
Index” (BASRI) and “Modified Stoke AS Spinal Score” (mSASSS) to give a new modified 
index useful for definition of PsA types (Helliwell, 2009; Coates &  Helliwell, 2010). The 
concept of SpA that comprises a group of interrelated disorders has been recognised since 
the early 1970s. While the European Spondyloarthropathy Study Group (ESSG) criteria and 
the Amor criteria have been developed to embrace the entire group of SpAs, new criteria for 
psoriatic arthritis have been developed recently. The CASPAR study, a large one of more 
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than 1000 patients, led to a new set of validated classification criteria for psoriatic arthritis. 
Since their publication in 2006 the CASPAR criteria are widely used in clinical studies. In AS, 
the 1984 modified New York criteria have been used widely in clinical studies and daily 
practice but are not applicable in early disease when the characteristic radiographical signs 
of sacroiliitis are not visible but active sacroiliitis is readily detectable by magnetic resonance 
imaging (MRI). This led to the concept of axial SpA that includes patients with and without 
radiographic damage. Candidate criteria for axial SpA were developed based on proposals 
for a structured diagnostic approach. These criteria were validated in the “Assessment of 
Spondyloarthritis International Society” (ASAS) study on new classification criteria for axial 
SpA, a large international prospective study. In these new criteria, sacroiliitis showing up on 
MRI has been given as much weight as sacroiliitis on radiographs, thereby also identifying 
patients with early axial SpA. Both the CASPAR and the ASAS criteria for axial SpA are 
likely to be of use as diagnostic criteria to define PsA types (Rudwaleit & Taylor, 2010). 
Early PsA is a condition with a consistent risk of clinical progression. Abundant entheseal 
involvement is a distinctive clinical aspect that helps discriminate early PsA from RA. Today 
its detection, followed by a rapid therapeutic intervention, predicts a better clinical outcome 
(Scarpa et al., 2009). Different to RA, the joint distribution in PsA tends to be asymmetrical 
and oligoarticular (< five joints). Distal joints, particularly the DIP joints of the hands, are 
more frequently affected; joint tenderness tends to be less; and dactylitis, enthesitis and axial 
or spinal involvement are more frequent. Unlike seronegative SpA, 40% of patients with 
PsA suffer from a sacroiliitis that tends to exhibit an asymmetrical rather than a symmetrical 
distribution. Other features of PsA include the absence of rheumatoid nodules, of 
rheumatoid factor in the blood and, in some instances, the presence of iritis, mucous 
membrane lesions, urethritis, bowel inflammation and tendonitis. PsA is often characterized 
by plain film evidence of juxta-articular new bone formation and magnetic resonance 
imaging evidence of enthesitis. Eighty per cent of cases are associated with psoriatic nail 
changes such as pitting, ridging, oil spots and nail plate thickening. Although PsA is 
preceded by cutaneous psoriasis in 75% of cases, in 10–15% of cases the arthritis precedes 
the psoriasis, suggesting that the two diseases may be controlled by different mechanisms or 
that a common etiology, may remains dormant in the synovial compartment. The mean time 
to onset of arthritis among those with pre-existing cutaneous psoriasis is 10 years, but delays 
have been reported of up to 20 years. Few instances of PsA without psoriasis have been  
described because most cases resembling PsA in the absence of personal or family history of 
skin disease are classified as an undifferentiated SpA (Ciocon & Kimball, 2007; Garg & 
Gladman, 2010). Patients with clinical symptoms and signs of PsA and a family history of 
psoriasis can be classified as having PsA sine psoriasis. The clinical spectrum of PsA sine 
psoriasis is broad. It is identified by dactylitis and/or DIP arthritis, HLA-Cw6, and a family 
history of psoriasis following the CASPAR criteria (Olivieri et al., 2009). Outcome 
measurement is a key part of study design but presents particular challenges in SpA. 
Enthesitis and dactylitis are typical features of SpA and validated scoring systems for both 
are available, although the majority of enthesitis outcome measures are validated in AS 
only. Assessment of axial disease is well researched in AS and composite outcome measures 
are routinely used. However, assessment of axial disease in predominantly peripheral 
arthritis, such as PsA, is problematic and under-researched. Extensive research in 
dermatology has provided multiple outcome measures for skin psoriasis. The PASI remains 
the most common outcome measure used, despite the fact that significant problems exist 
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with this scale and that newer scoring methods and modifications of the PASI show better 
validity. Nail psoriasis is accurately measured by detailed scoring systems but these can be 
time-consuming (Coates & Helliwell, 2010). The number of actively inflamed joints as 
measure of disease activity and the number of clinically deformed joints as measure of 
damage were significantly related to the “Health Assessment Questionnaire” (HAQ) score 
also useful for defining PsA types. Furthermore, interaction terms for illness duration with 
the number of actively inflamed joints were statistically significant, with or without 
inclusion of the erythrocyte sedimentation rate and morning stiffness in the model. The 
influence of disease activity on HAQ scores declines with increased disease duration 
(Husted et al., 2007). 
Patients with psoriasis from 13 dermatological hospitals and 129 dermatological private 
practices and outpatient clinics in Germany revealed that nineteen per cent of the patients 
had PsA, including 14.8% previously confirmed and 4.2% newly diagnosed disease. 
Another 7.7% had intermittent but clinically unspecific joint symptoms, which could not 
be clearly attributed to PsA. About half (49.7%) of the patients with PsA had at least 1 
swollen joint and 84.9% (n = 287) suffered from joint pain. Patients suffering from pain 
marked an average of 8.7 joints on a diagram as painful out of a possible 28. The mean 
number of swollen joints among the affected patients amounted to an average of 6.8. 
There are still a significant number of patients suspected of having joint involvement 
without ever having been diagnosed with PsA. Published data indicate that progression 
of joint damage and functional disability can be prevented if adequate treatment is started 
promptly (Radtke et al., 2009). 
6.3 Psoriatic arthritis and genetics 
The genes involved, in PsA are HLA genes of class I MHC alleles, on the HLA-B and HLA-C 
loci. Psoriasis is linked to HLA-Cw6 allele. Twenty percent of PsA patients with peripheral 
joint involvement displayed HLA-B27, a value that climbs to 70% in patients with PsA type 
spine involvement (Amherd-Hoekstra et al., 2010). The overlap in associated HLA antigens 
for both diseases (B13, B17, B57, Cw6, and DR7) suggests a shared genetic predisposition 
(Barton, 2002). Psoriasis and PsA are heritable diseases. Polymorphisms in the genes 
encoded in the MHC region have consistently been associated with psoriasis and PsA and 
account for about 30% of the genetic risk. In psoriasis, the association has been primarily 
with class I antigens: HLA-B13, HLA-B17, HLA-Cw6, and HLA-Cw7, the strongest 
association being with HLA-Cw6. Typing for HLA-Cw6 may have potential clinical utility, 
as it is associated with early onset of psoriasis, higher incidence of guttate or streptococcal 
induced disease flares, and more severe disease. PsA is also associated with multiple HLA 
antigens, many of which are similar to psoriasis antigens, as the two diseases are 
interrelated (O’Rielly & Rahman, 2010). However, specific associations do exist for the 
inflammatory arthritis, as HLA-B27 is associated with greater spinal involvement, and B38 
and B39 with peripheral polyarthritis. HLA antigens are also prognostic factors, as HLA-B39 
alone, HLA-B27 in the presence of HLA-DR7, and HLA-DQw3 in the absence of HLA-DR7 
all confer an increased risk for disease progression. The RA shared epitope was found to be 
associated with radiologic erosions among patients with PsA. Patients with PsA carrying 
both HLACw6 and HLA-DRB107 alleles were determined to have a less severe course of 
arthritis. Recently, the results of multiple well powered genome-wide association studies 
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have identified several loci outside the MHC region associated with psoriasis risk, including 
three genes involved in interleukin (IL)-23 signaling (IL-23R, IL-23A, IL-12B), two genes that 
regulate nuclear factor-κB signaling (TNIP1, TNFAIP3), and two genes involved in the 
modulation of T-helper type 2 immune responses (IL-4, IL-13) (Bowes & Barton, 2010). 
Genetic epidemiologic studies have shown that both diseases have a strong genetic 
component. Environmental risk factors including streptococcal pharyngitis, stressful life 
events, low humidity, drugs, HIV infection, trauma, smoking and obesity have been 
associated with psoriasis and PsA (Barton, 2002; Cantini et al., 2010). PsA is even more 
strongly influenced by genes than is cutaneous psoriasis (Moll & Wright, 1973; Chandran & 
Raychaudhuri 2010). Family studies continue to suggest a large genetic contribution to PsA. 
Using a candidate gene approach, genes confirmed to be associated with psoriasis vulgaris 
have also been found to be associated with PsA: HLA-Cw-0602, IL23R, and IL12B (Castelino 
& Barton , 2010). 
6.4 Psoriatic arthritis interleukins and biomarkers 
A key objective of the assessment working group of the “Group for Research and 
Assessment of Psoriasis and Psoriatic Arthritis” (GRAPPA) was to identify, develop, 
evaluate, and validate outcome measures for use in clinical trials of PsA and in clinical 
practice useful in defining PsA types (Mease, 2008) . Biomarkers are helpful in screening 
patients with psoriasis for PsA types. Patients with psoriasis  satisfying CASPAR criteria for 
PsA were  analyzed for IL-12, IL-12p40, IL-17, TNF super family members (TNFSF14), 
MMP-3, RANK ligand (RANKL), osteoprotegerin (OPG), cartilage oligomeric matrix protein 
(COMP), C-propeptide of Type II collagen (CPII), collagen fragment neoepitopes Col2-3/4 
long mono (C2C), Col2-3/4short (C1-2C) and highly sensitive CRP (hsCRP). Serum levels of 
RANKL, TNFSF14, MMP-3 and COMP independently associated with psoriatic disease. 
Twenty six PsA patients (mean swollen and tender joint count: 16, swollen joint count: 5) 
were then compared with 26 patients who had psoriasis alone. Increased levels of hsCRP, 
OPG, MMP-3 and the CPII:C2C ratios were independently associated with PsA and are 
biomarkers for PsA in patients with psoriasis (Chandran et al., 2010). 
6.5 Psoriatic arthritis and cardiovascular disease 
Immune-mediated inflammatory diseases (IMIDs), including RA and SpA, are associated 
with increased cardiovascular morbidity and mortality, independent of the established 
cardiovascular risk factors. The chronic inflammatory state, a hallmark of IMIDs, is 
considered to be a driving force for accelerated atherogenesis. Consequently, aggressive 
control of disease activity has been suggested to be instrumental for cardiovascular risk 
reduction (Bisoendial et al., 2009).   
Patients with PsA have an increased incidence of CVD and cardiovascular risk factors such 
as smoking, hypertension, and metabolic syndrome compared to the normal population as 
well as nonconventional risk factors such as raised levels of homocysteine and excessive 
alcohol consumption. In patients with PsA, carotid wave pulse velocity, a measure of 
arterial stiffness, was significantly higher. Patients with psoriasis were found to have 
increased coronary artery calcification in direct imaging study compared to controls. Two 
case control studies also demonstrated that patients with PsA had a higher prevalence of 
subclinical atherosclerosis as measured by arterial intima-media wall thicknes (IMT) and 
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endothelial dysfunction without overt CVD. In patients without clinical CVD 35% had 
increased IMT despite having low cardiovascular risk. One hundred two patients with PsA 
had a higher prevalence of type II diabetes mellitus and hypertension, and an increased 
prevalence of HDL cholesterol, apolipoprotein A1 levels, lower total cholesterol and LDL 
cholesterol levels, and lower total cholesterol to HDL cholesterol ratio. Chronic 
inflammation has been shown to play a role in the development of atherosclerosis now 
considered as an inflammatory, autoimmune like disease. Both the innate immune system 
and T helper-1 lymphocytes appear to be involved in atherogenesis. This is similar to the 
pattern of immune mediated inflammation in psoriasis and PsA. It is possible that psoriasis 
and PsA produce chronic, systemic inflammation, with higher levels of inflammatory cells 
and cytokines invoking endothelial inflammation and plaque formation in the vascular 
system (Tobin et al., 2010). The increased risk for CVD in RA is well known and 
inflammation appears to play a pivotal etiological role. There is now substantial interest in 
whether or not PsA is also associated with an enhanced cardiovascular risk. In all patients 
CVD was defined as a history of myocardial infarct (MI), stroke and/or transient ischemic 
attack verified by written documentation of the event. The prevalence of CVD was 10% in 
patients with PsA compared with 12% in patients with RA (Jamnitski et al., 2010).  Flow-
mediated dilatation (FMD) was significantly impaired in PsA patients without traditional 
cardiovascular risk factors or CVD. Another study also showed a higher prevalence of 
subclinical atherosclerosis, as measured by carotid IMT, among PsA patients. As in RA, 
CVD and their risk factors including hyperlipidaemia, diabetes mellitus and hypertension 
were more common in PsA patients. However, mortality in patients with PsA, in a single 
center cohort was not significantly different from the general population in England. No 
increased risk of death was observed in this cohort (Buckley et al., 2010).  In a population of 
patients with PsA 23.3% had renal abnormalities as defined by creatinine clearance below 
the lower cut off of normal distribution and urinary excretion of albumin more than 25 
mg/24 hrs. These patients were significantly older at the time of the study, older at joint 
disease onset, had longer skin disease duration, increased serum levels of beta2-
microglobulin, and higher incidence of increased erythrocyte sedimentation rate and C 
reactive protein levels (Alenius et al., 2001). 
6.6 Psoriatic arthritis, metabolic syndrome and malignancies 
To evaluate the prevalence of the metabolic syndrome (MetS), patients with RA, AS and PsA 
were recruited for a study of atherosclerotic risk factors and the MetS, defined according to 
the 2009 Joint Statements using the Asian criteria for central obesity. The prevalence of MetS 
was significantly higher in PsA (38%) than RA (20%) or AS (11%). Patients with PsA had 
significantly higher prevalence of impaired fasting glucose (30%), low HDL-cholesterol 
(33%), high triglyceride (21%), central obesity (65%) and high blood pressure (56%). Patients 
with PsA, but not RA or AS, have a significantly higher prevalence of the MetS syndrome 
compared to the general population. Among the three diseases studied, PsA has the highest 
prevalence of the MetS and is associated with highest cardiovascular risk (Mok et al., 2010; 
Papo et al., 2010)  
A cohort analysis of SpA patients who were followed up prospectively from 1978 to 2004 at 
the University of Toronto PsA Clinic was performed. Of the 665 patients included, 68 
(10.2%) developed a malignancy at an average age of 62.4 years. The most frequently seen 
malignancies were breast (20.6%), lung (13.2%), and prostate (8.8%) cancer. However, the 
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incidence of malignancy in the large PsA cohort did not differ from that in the general 
population (Rohekar et al., 2008). 
6.7 Inflammatory markers C-reactive protein (CRP) and complement 5a (C5a) in 
patients with psoriatic arthritis, before and after treatment with amastigote antigens 
Inflammatory markers C-reactive protein (CRP) and complement 5a (C5a) assayed in two 
PsA patients decreased significantly in serum after treatment with 6 doses of AS200 DEAE 
fractions 3 + 4 Leishmania amastigotes antigens at 300 µg/dose (Fig 1). The Leishmania 
antigens decreased markedly the TNFǂ concentration in supernatants from PBMC in both 
patients and controls (Fig 1 to 5 adapted from O’Daly & Gleason, 2010c, by permission of 
the associate editor) 
 
Fig. 1. Psoriatic patients (A and B) with 6 doses of AS200 at 300 µg/dose before and after 
treatments. Both patients had PASI reduction 61.6% and 66.4% respectively and biopsies 
with excellent improvement evidenced by decrease of epidermal layer and absence of 
inflammatory cells in epidermis and dermis in comparison to placebo (Rehydragel). 
6.8 TNF- in psoriatic patients and ConA induced hepatitis in mice 
PBMC of patients and controls were stimulated with concanavalin A (ConA); ConA+AS100-
2 L(L)chagasi antigens and compared to no treatment as control. The Leishmania antigens 
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decreased markedly the TNF concentration in supernatants from PBMC in both patients 
and controls (Fig 2). In mice ConA induced hepatitis, injection of 50 µg AS100-2 L(L)chagasi 
antigens subcutaneously (SC) decreased serum TNF as compared to placebo (PBS) in 8 
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Fig. 2. PBMC of patients and controls after stimulation with concanavalin A (ConA), ConA + 
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Fig. 3. Serum TNF in ConA induced hepatitis in mice (n=3 per group). After SC injection of 
50 µg AS100-2 L. chagasi antigens, TNF decreased significantly as compared to placebo 
(PBS) at 2, 4 and 8 hours observation period. STDEV < 5% of average. 
Serum IL-1ǃ, 8 hours after SC injection of AS200 L(V)brasiliensis +RH and AS100-1+RH in 
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positive control dexamethasone (Fig 4). AS100-2 L(L)chagasi antigens decreased proliferation 


















































Fig. 4. Serum IL-1ǃ in ConA induced hepatitis in mice (n=3 per group). IL-1ǃ was 
determined after 8 hours of SC injection of the following products: 1- 50 µL placebo (PBS) 2- 
50 µL PBS+Rehydragel (RH), 3- 50 µg/mice L(V)brasiliensis AS200 fraction 3 and 4 + RH, 4- 
AS100-1(4 species)+RH and 5- 1 mg/Kg/mice dexamethasone. Control normal mice, 
received no treatment. IL-1ǃ decrease significantly after treatment with L(V)brasiliensis 
AS200 antigens 3 and 4, or polyva;ent AS100-1 vaccine, similar to dexamethasone as 
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Fig. 5. In vitro proliferation of cutaneous T cell lymphoma cells at different concentrations of 
AS100-2 (L) chagasi leishmania antigens as compared to PBS after 24 hours of culture. Values 
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6.9 Lymphocyte subsets in patients with psoriatic arthritis 
As more skin disease is present in PsA patients, more inflammation is found in the joints, 
suggesting a link between skin and joint inflammatory processes; since both were 
exacerbated in the PASI 100 and PASI 75 groups and also needed higher number of doses to 
achieve a lower AS, tender joints and nail changes values (O’Daly et al., 2011). Absolute 
values of gated LS before treatment decreased in this order: CD8+HLA-, CD8+HLA+, CD4+, 
CD8+CD3+, CD8+CD3 in PBMC as PASI increased, suggesting migration of CD8+ cells 
from the blood to the joints and skin. Contrary to the previous finding, LS: CD8+CD4-, 
CD3+CD8-, HLA+CD8-, CD19+, CD8+CD4+,  IgA+, IgD+, IgM+, IgE+, and IgG+ increased 
in PBMC as PASI increased  suggesting activation and proliferation by unknown antigens 
and subsequent migration to the blood. The LS quantification in this group of PsA patients 
only (n=508) were different (O’Daly et al., 2011) to the LS quantified in the psoriasis skin 
disease trial (n=2770, O’Daly et al., 2010b), since in PsA the majority belonged to the CD8+ 
phenotype, a T cell key in the PsA inflammatory process as described by many authors. In 
PsA patients there is also evidence of T cell recirculation before treatment and a vicious 
cycle with T and B cells migrating between blood and skin and joints. After treatment with 
nine doses of AS100-1 Leishmania amastigotes antigens, a dramatic decrease in LS belonging 
to T and B cells, in PBMC was observed, as PASI, AS, tender joint counts, and nail changes 
returns to normal values and the vicious cycle disappeared (O’Daly et al., 2011). AS100-1 
had a cellular not humoral immune response as supported by the DTH and ELISA results in 
humans and guinea pigs (O’Daly et al. 2009a; O’Daly et al., 2009b; O’Daly et al., 2010a). All 
psoriatic patients were DTH positive after the third vaccination with AS100-1, but no ELISA 
antibodies were detected in serum from these volunteers up to 6 doses of vaccine (O’Daly et 
al., 2009a). This suggests that the immunological response to AS100-1 after TLCK treatment 
and NP-40 extraction was mediated by immunization of T-regulatory cells, with no 
antibody production, a novel mechanism that may play a role in decreasing inflammation in 
psoriatic skin. Amastigote peptides may induce Th3 regulatory T cells producing IL-10 that 
inhibits Th1 and Th2 cell cytokine production and induced peripheral cell tolerance. 
6.10 Psoriatic arthritis therapies  
Psoriasis is one of the most prevalent chronic inflammatory diseases with a high economic 
impact. The disease persists for life, and the patient has an increased risk of CVD. One out of 
five patients develops PsA. The clinical picture of psoriasis is highly variable with regard to 
lesion characteristics and the severity of disease. To improve the management of psoriasis, 
guidelines must be followed and all appropriate topical and systemic treatment options 
must be tried, with clearly defined treatment goals. The spectrum of established systemic 
treatments for psoriasis has been extended by the biologics (Mrowietz & Reich, 2009). 
PsA is an inflammatory arthritis occurring in up to 30% of patients with psoriasis. Its clear 
distinction from RA has been described clinically, genetically, and immunohistologically. 
Therapies that target cells, such as activated T cells, proinflammatory cytokines, and TNFǂ, 
are used extensively today. A variety of items are evaluated including joints, skin, 
enthesium, dactylitis, spine function, quality of life, and imaging assessment of disease 
activity and damage (Ceponis & Kavanaugh, 2010). The performance of treatments in these 
various domains have being evaluated by GRAPPA, and improved measures are being 
developed and validated specifically for PsA. Traditional therapies for PsA like non 
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steroidal anti-inflammatory drugs (NSAIDs), oral immunomodulatory drugs, topical 
creams, and light therapy have been helpful in controlling both musculoskeletal and 
dermatologic lesions of the disease, but may eventually show diminished benefit, and may 
produce severe toxicities as side effects (Mease, 2006). 
The primary goals in the treatment of PsA are reduction of pain; improvement in the other 
signs and symptoms of disease, including skin and nail involvement; optimization of 
functional capacity and quality of life; and inhibition of the progression of joint damage. 
These goals should be achieved while minimizing potential toxicities from treatment. The 
management of PsA should simultaneously target arthritis, skin disease, and other 
manifestations of PsA, including involvement of the axial skeleton dactylitis, enthesitis, and 
eye inflammation. In this respect targeted biological agents, primarily TNFǂ inhibitors, have 
emerged as generally well tolerated and highly effective alternatives to traditional “Disease 
Modifying Anti Rheumatic Drugs” (DMARDs) (Mease, 2010b)   
PsA was considered as a less damaging disease than RA. In early arthritis 50% of patients 
showed significant joint damage developing erosions in the first 2 years even if DMARDs 
were used as treatment. The treatment should aim to preserve function, prevent disability 
and maintain quality of life. The therapeutic approach has employed treatments to benefit 
both the skin and joints with minimal adverse effects, and to prevent subsequent disability 
and damage, inflammation i.e. synovitis which must be arrested and controlled early. In this 
respect combination therapy with conventional DMARDs and biologic drugs, like TNFǂ 
inhibitors, has made significant progress in the last 10 years. A remission rate of 58% of 
patients treated with DMARD and biologic therapy for 12 months has been achieved 
(Wollina et al., 2010). 
Nail involvement in psoriasis is typically overlooked; it can affect up to 50% of patients 
with psoriasis and cause functional impact as well as psychological stress that affect 
quality of life. Psoriatic patients with nail disease have more severe skin lesions, and 
higher rate of unremitting PsA. The current management of nail psoriasis includes topical, 
intralesional and systemic therapies, although little clinical evidence is available on the 
effectiveness of conventional treatments. Biologic agents are beginning to emerge as a 
viable option to treat patients with both cutaneous and nail clinical manifestations of 
psoriasis and PsA (Vena et al., 2010).  
Although they can have some beneficial effect on skin disease and peripheral arthritis, 
there is lack of evidence for DMARDs, such as methotrexate (MTX), Leflunomide (LEF), 
cyclosporine (CsA), and sulfasalazine (SSZ) in affecting dactylitis or enthesitis, and they 
are clearly ineffective in axial disease. Systemic glucocorticoids may cause a flare of 
psoriasis if treatment is stopped too quickly, and should be used with caution in PsA. In 
contrast, biologics, particularly TNFǂ inhibitors seem to be beneficial in skin psoriasis and 
across of all the manifestations of PsA, including arthritis, skin and nail disease, spinal 
disease, enthesitis and dactylitis. They also improve quality of life and inhibit joint 
damage. All the currently used TNFǂ inhibitors appear to have comparable efficacy and 
safety profiles in patients with PsA. They can be used as monotherapy or in combination 
with MTX or other traditional DMARDs. Initiation of anti-TNFǂ agents is recommended 
for patients who failed one of the traditional DMARDs or as an initial therapy in patients 
who have poor prognosis. Other biological agents, including alefacept and abatacept, 
appear to be less potent than TNFǂ inhibitors in PsA and their use is likely to be reserved 
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for patients who failed or cannot be treated with TNFǂ inhibitors. These agents are 
usually used in combination with other DMARDs. The Efficacy of ustekinumab in the 
treatment of PsA has been recently reported and is presently under further investigation 
(Mease, 2009; Mease, 2010a)  
Results from clinical trials of biologic anti-TNFǂ drugs confirmed the biological relevance of 
TNFǂ function in the pathogenesis of chronic noninfectious inflammation of joints, skin and 
gut. Up to April 2009, more than two million patients worldwide have received the first 
marketed drugs, namely the monoclonal anti-TNFǂ antibodies infliximab and adalimumab 
and the soluble TNF receptor etanercept. All three are equally effective in RA, AS, psoriasis 
and PsA, and only the monoclonal antibodies are effective in inflammatory bowel disease. 
The spectrum of efficacy with anti-TNFǂ therapies includes diseases such as systemic 
vasculitis and sight-threatening uveitis. New adverse effects are recognized, like 
development of new onset psoriasis. Reactivation of latent tuberculosis remains the most 
important safety issue of anti-TNFǂ therapies (Sfikakis, 2010). RA, AS and PsA are 
commonly thought of as inflammatory diseases that affect younger individuals. The safety 
profiles for etanercept, infliximab and adalimumab in patients of 65 years or more, anti-
TNFǂ treatments for an active inflammatory disease such as RA, AS or PsA, or psoriasis 
were analyzed. Anti TNFǂ treatment is a safe option possibly leading to better disease 
outcome (Migliore et al., 2009).  
Altogether there is sufficient reason not to dismiss traditional agents for use in PsA because 
of lack of evidence. Also, due consideration must be given to the considerable cost of 
biologic treatments versus traditional treatments. The role of combination therapy with 
TNFǂ inhibitors is an important one, especially considering that 30%–40% of patients in the 
TNFǂ inhibitor trials have been on MTX as concomitant medication (McHugh, 2009). 
Traditional systemic therapies for psoriasis, such as MTX, CsA, retinoids or psoralen plus 
ultraviolet light (PUVA) therapy, have a potential for long-term toxicity and may not always 
provide sufficient improvement of the disease. Biological therapies for the treatment of PsA 
are defined by their mode of action and can be classified into three categories: the T-cell 
modulating agents (alefacept and efalizumab), the TNFǂ blockers, (adalimumab, 
certolizumab, etanercept, golimumab and infliximab) and the inhibitors of interleukin IL-12 
and IL-23 (ustekinumab and briakinumab) (Weger, 2010). DMARDs remain the first choice 
for the treatment of peripheral arthritis despite scarce evidence of their efficacy or ability to 
halt radiographic progression. TNFǂ antagonists have the greatest level of evidence for 
symptom control and radiographic progression. They are currently used after the failure of 
DMARDs to effectively treat peripheral arthritis, enthesitis, and dactylitis, and are the first 
choice when axial disease predominates. Despite the use of these treatments, 30% to 40% of 
patients will still have active disease. Among new drugs, evidence of efficacy has already 
been published with regard to anti-IL12/23 monoclonal antibody (ustekimumab) and 
golimumab (Soriano &, Rosa, 2009)  
For a long time, the endothelial covering of the vessels has been considered an inert 
surface. On the contrary, the endothelial cells are active and dynamic elements in the 
interaction between blood and tissues. The control of the vessel basal tone is obtained by 
the complex balance between the relaxing and contracting endothelial factors. Previous 
clinical studies show that patients suffering from RA and other autoimmune 
rheumatologic pathologies are at high risk of death being prematurely affected by 
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atherosclerosis and CVD. Blocking TNFǂ by biological drugs improves the endothelial 
function. The effects of two anti-TNFǂ drugs (infliximab and etanercept) on the 
endothelial function were evaluated by FMD, which was measured in the brachial artery 
before and after treatment. 36 patients were enrolled 25 with RA and 11 with PsA. They 
were divided into three groups: 10 patients were treated with etanercept, 13 with 
infliximab, and 13 with DMARDs. The carotid IMT was measured and the endothelial 
function was evaluated by FMD measurement in the brachial artery, before treatment, 1 h 
after the beginning of treatment and after 8–12 weeks. No statistically significant 
difference between the three groups before treatment was found for the ultrasonographic 
evaluation of the carotid IMT. On the contrary, the differences between FMD values 
before and after the treatment in the patients treated with etanercept and in the patients 
treated with infliximab were statistically significant. Long-term evaluation for infliximab 
and etanercept was performed by comparing the FMD values, 8 and 12 weeks after the 
first treatment. After 8 weeks, FMD value was similar to the value recorded at enrollment 
in the infliximab group and the FMD values in the etanercept group after 12 weeks 
showed a not statistically significant reduction of vasodilatating effect. Drugs in patients 
affected by autoimmune arthritis can modify the endothelial function, as indicated by the 
induced FMD changes, but the long-term effect tends to be considerably reduced 
(Mazzoccoli et al., 2010)  
Significantly diminished values for swollen and tender joints, patients global and pain 
assessments, doctor’s global assessment of disease activity, erythrocyte sedimentation rate, 
C-reactive protein, and “Health Assessment Questionnaire” (HAQ) score were observed 
within 3 months after commencement of both infliximab and etanercept. Values remained 
significantly lower throughout the 24 months of follow up. ACR20 response at 3 months 
was 79% (n = 22/28) for infliximab and 76% (n = 34/45) for etanercept. The first biological 
drug was discontinued in 16% due to lack of effectiveness and in 6% due to adverse events 
(Virkki et al., 2010). It is unclear if skin cancer risk is affected by the use of 
immunomodulatory medications in RA, psoriasis, and PsA. RA may potentiate the risk of 
cutaneous malignancy and therefore dermatologic screening in this population should be 
considered. The use of immunomodulatory therapy in RA, psoriasis, and PsA may further 
increase the risk of cutaneous malignancy and therefore dermatologic screening 
examinations are warranted in these groups. More careful recording of skin cancer 
development during clinical trials and cohort studies is necessary to further delineate the 
risks of immunomodulatory therapy (Krathen et al., 2010). 
PsA provides an ideal disease model in which to investigate the bioactivities of potentially 
therapeutic cytokines at multiple sites of tissue inflammation. The effects of subcutaneous 
rhIL-10, an anti-inflammatory cytokine, was investigated for 28 days in a double-blind, 
placebo-controlled study in PsA patients. Synovial/skin biopsies, peripheral blood 
leukocytes, articular magnetic resonance images, and clinical disease activity scores were 
obtained sequentially. Modest, but significant clinical improvement in skin, but not 
articular disease activity scores with only minor adverse effects was observed. Type 1, but 
not Type 2 cytokine production in vitro was suppressed in human rhIL-10 treatment 
compared with placebo recipients. Similarly, TNFǂ and IL-1ǃ, production in whole blood 
stimulated with LPS in vitro was reduced, whereas serum soluble TNFRII levels were 
elevated, indicating suppression of monocyte function. Decreased T cell and macrophage 
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infiltration in synovial tissues was accompanied by reduced P-selectin expression. 
Moreover, suppressed synovial enhancement on magnetic resonance imaging and 
reduced (v)ǃ(3) integrin expression on von Willebrand factor(+) vessels were observed. 
Together these data demonstrate that a short course of IL-10 modulates immune 
responses in vivo via diverse effects on endothelial activation, leukocyte recruitment and 
effector functions. Such biological changes may result in clinically meaningful 
improvement in disease activity (McInnes et al., 2001).  
Biologic agents should be considered for use solely in children with psoriasis that is 
refractory to conventional therapies, including children with severe, widespread, refractory 
pustular, plaque or PsA. Etanercept appears to have resulted in less severe side effects 
compared to infliximab in the juvenile RA population. Serious adverse events (including 
infection), have been reported in the literature and should be taken into account before 
beginning treatment with any biologic agent (Marji et al., 2010).  
The socioeconomic scenario of PsA is similar to RA. Current treatments do not achieve 
remission of symptoms or prevention of the appearance of damage in the early stage of PsA 
nor the blocking of PsA progression in old cases. The current management of PsA includes 
NSAIDs, corticosteroids, DMARDs and anti-TNF-ǂ alpha blocking agents. These biologic 
drugs are more effective than traditional DMARDs on inflammation, quality of life and 
function and can inhibit the progression of the structural joint damage. Recent advancement 
in the immunopathogenesis of PsA has permitted the development of novel drugs including 
new TNF-ǂ blockers, IL-1, IL-6, IL-12, IL-23 and IL-17 inhibitors, co-stimulator modulation 
inhibitors, B-cell depleting agents, small molecules and receptor activator of NF-
kappaB/receptor activator of NF-kappaB ligand inhibitors (Olivieri et al., 2010). 
Baseline clinical characteristics including demographics, previous DMARDs response, 
tender and swollen joint counts, early morning stiffness, pain visual analogue score, patient 
global assessment, C reactive protein (CRP) and HAQ were collected. At 12 months 
remission, defined according to the disease activity score using 28 joint count and CRP 
(DAS28-CRP), was achieved in 58% of PsA patients compared to 44% of RA patients. DAS28 
remission is possible in PsA patients at one year following anti-TNFǂ therapy, at higher 
rates than in RA patients and is predicted by baseline HAQ (Saber et al., 2010). 
Therapy for inflammatory joint diseases, such as RA, AS and PsA, includes DMARDs. 
Conventional DMARDs are used as monotherapy or in combination and include MTX, LEF, 
azathioprine, CsA, hydroxychloroquine, SSZ, gold and minocycline. Biologic therapies are 
TNFǂ inhibitors, T-cell modulators and B-cell depleters. They have all been shown to have 
clinical efficacy and are able to retard structural damage (Vaz et al., 2009). 
7. Leishmaniasis, the tropical disease root of the serendipity finding 
7.1 What is Leishmaniasis? 
Leishmaniasis is a globally distributed zoonosis mostly centered in the tropics and 
subtropics, with humans serving as accidental hosts. Due to the prevalence of the disease, 
one-tenth of the world’s populations (600 million people) are at risk of infection. Globally, 
there are approximately 12 million cases and the incidence of new visceral leishmaniasis 
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(VL) and cutaneous (CL) infections are approximated 0.5 and 1.5 million new cases each 





Fig. 6. Cutaneous and Visceral Leishmaniasis in our planet  
7.2 Leishmania life cycle and suppression of antigen display 
Extracellular procyclic promastigotes in the vector (sandfly) mature to metacyclic 
promastigotes (motile) that eventually evolve to amastigotes (nonmotile) once they enter 
cells in the vertebrate host after the insect bite. The amastigote eventually evolves back to 
the promastigote form in the vector, after a blood meal in infected hosts, closing the cycle. 
The mature infective metacyclic promastigotes have surface glycoconjugates such as 
glycosylinositolphopholipid (GIPL) and lipophosphoglycan (LPG), wich is a virulence factor 
of the mature promastigote and inhibits the action of the complement system (Okwor & 
Uzonna, 2009). Once inside the host, metacyclic promastigotes are taken up by macrophages 
through binding to complement receptors 1 and 3 or C reactive protein receptor, without 
leading to the activation of the macrophage. Approximately 24–72 hours after being taken 
up by the macrophage, the promastigotes transform into round nonmotile intracellular 
amastigotes with no surface GIPL or LPG. The amastigotes begin to multiply in the 
parasitophorous vacuole inside the macrophage (Figure 7), suppressing IFN-γ and the 
production of nitric oxide (NO) and superoxide (Awasthi et al., 2004; Handman, 2001). The 
immunological response in humans and experimental animals is induced by the amastigote 
form (intracellular), and not by extracellular promastigotes form, which enters the host 
target cell immediately after infection and is not seen by the host immune system. 
Amastigotes inhibit antigen presentation by repressing the expression of Class I and Class II 
MHC gene products, both basally and following stimulation with IFNγ (Reiner et al., 1987; 
Reiner det al., 1988). On the other hand, macrophages infected with L(L)major may express 
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normal levels of MHC class II molecules, but inhibit antigen presentation by interfering with 
the loading of antigens onto the MHC class II molecule (Fruth et al., 1993). An alternative 
suppression technique used by several Leishmania species is to sequester the MHC II 




Fig. 7. Life cycle of leismania parasites and initial cutaneous lesion 2-3 weeks after bite 
7.3 How do vertebrates defend against Leishmaniasis? 
After being bitten, a granuloma composed of granulocytes, lymphocytes, epithelioid cells, 
monocytes, macrophages, and fibroblasts forms at the site of infection. In addition to killing 
parasites, activated macrophages produce different cytokines such as TNFǂ, IL-6, IL-18, IL-
12, and IFNγ inducing a protective Th1-type immune response (Awasthi et al., 2004; 
Handman, 2001). Analyses of immune responses in natural and experimental (healthy 
human volunteers) infections show that the clear Th1/Th2 T cell responses to L(L) major seen 
in murine studies do not occur. Instead, a typical mixed Th1/Th2 response is observed with 
PBMC from patients secreting varying amounts of IFNγ, IL-10, and IL-4 depending on the 
clinical stage of the disease. CD4+ and CD8+ cells contribute to IFNγ and TNFǂ production 
in infected patients (Okwor & Uzonna, 2009). Residual parasites remain in the host forever 
and can be reactivated in the immunocompromised hosts and by AIDS (Fernandez-
Guerrero et al., 1987; Rodriguez Coura et al., 1987; Rosenthal et al., 1988; Scaglia et al., 1989; 
Altges et al. 1991).  
TNF plays a central role in the defense against intracellular infections with Leishmania, a 
disease that ends fatally in TNF–/– mice (Reiner et al., 1987). Resolution of an established 
infection is mediated by IFN-γ produced by CD4+ T cells in C57BL/6 resistant mouse strains 
(Reiner et al., 1988). The IFN-γ response allows macrophages to develop leishmanicidal 
activities as expression of inducible nitric oxide synthase (iNOS) and NO. In contrast, 
BALB/c susceptible strain develops IL-4- and IL-10-mediated CD4+ T cell response. 
Rheumatoid arthritis patients treated with TNF antagonists have reoccurrence of 
leishmaniasis. After blocking TNF, Leishmania donovani-infected mice were unable to 
www.intechopen.com
 Psoriasis – A Systemic Disease 
 
40
resolve the infection (Körner et al., 2010). VL is characterized by abundant parasites in the 
spleen, liver, and bone marrow. However, the parasite only establishes chronic infection in 
the spleen and bone marrow because infection in the liver is self-resolving within 6–8 weeks 
because of a Th1-dominated granulomatous response, characterized by high IFN-γ 
production (Stager et al., 2010).  
 
 Endemic area Hyperendemic area 
Study group Infected Noninfected p Infected Noninfected p 
Vaccinated 16 2,000  18 105  
Nonvaccinated 66 1,109 <0.001 52 50 <0.001 
Protective efficacy 85.9%   71%   
95% Confidence interval 81.8- 86.1   67.9- 74.3   
Table 1. Cases of leishmaniasis according to vaccination status, protective efficacy 
Neutrophils are rapidly recruited to the site of Leishmania inoculation, where they 
phagocytose the parasites, some of which are able to survive within these first host cells. 
Neutrophils can thus provide a transient safe shelter for the parasites, prior to their entry 
into macrophages where they will replicate (Charmoy et al., 2010).  
After vaccination with 3 doses of AS100-1  at 500 µg/500 µl , one month apart in the 
endemic area of “Valle Arriba” and in the hyperendemic area of “La Planta”  both in 
Guatire, Miranda State, Venezuela, (O’Daly et al., 1995a) protective efficacy were 85.9% 
and 71% respectively (Table 1). In the endemic area we found one person cured from 
plaque psoriasis one month after the third dose of vaccine. The vaccine also induced 
regression of leishmania lesions when used as immunotherapeutic agent as seen in Figure 
8 (O’Daly et al., 1995b) 
7.4 No prior sensitization required to recognize amastigote antigens 
Leishmania promastigotes sonicates induced in vitro proliferation and IFNγ production in 
PBMC from individuals that never had contact with Leishmania parasites. The proliferating 
T cell population was CD2+ in a frequency <1:10,000 a response that could be abolished 
after depletion of CD45RO+ memory cells from the PBMC (Kemp et al., 1992). Sera from 
volunteers vaccinated in the Leishmaniasis trial performed in Caracas, had ELISA negative 
values and a similar immunoblotting band pattern before vaccination, and 1 month after 3 
doses of the polyvalent vaccine using amastigote antigens from the four species present in 
AS100-1 (O’Daly et al., 1995a). Thus, normal CD2+ T cells (Kemp et al., 1992) and normal 
immunoglobulin from healthy volunteers that never experienced Leishmania infection 
reacted with Leishmania antigens in the immunoblotting assay. Interestingly psoriatic 
patients, DTH negatives to amastigote antigens, also recognized in the blastogenic assay 
Leishmania antigens and were distributed in two groups, low and high responders to 
Leishmania amastigote antigens before treatment (O’Daly et al., 2009b). 
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Age: 14 years, male
Ulcer 8.75 cm2 right leg
Evolution time: 1.5 months
1o. Generation vaccine:22 doses
Periodicity: weekly
Remission time: 5 months
Relapses: none.
Age: 14 years, male
Ulcer 8.75 cm2 right leg
Evolution time: 1.5 months
1o. Generation vaccine:22 doses
Periodicity: weekly
Remission time: 5 months
Relapses: none.
Immunotherapy with polyvalent leishmania vaccine
Before
After ft r 
 
Age:30 years, male
Ulcer: 3,14 cm2 right hand
Evolution time: 2 months
1a. Generation vaccine:14 doses
Periodicity: weekly
Remission time: 3,5 months
Relapses: none
Age:30 years, male
Ulcer: 3,14 cm2 right hand
Evolution time: 2 months
1a. Generation vaccine:14 doses
Periodicity: weekly
Remission time: 3,5 months
Relapses: none




Fig. 8. Treatment with AS100-1 polyvalent vaccine as immunotherapeutic agent in infected 
volunteers. 
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Furthermore, we have demonstrated a high DTH response with L. brasiliensis and L. 
chagasi protein (DEAE) fractions in vivo after treatment with AS100-1 suggesting a strong 
T cell response after treatment and confirming the absence of immunosuppression. The SI 
values obtained by protein (DEAE) fractions were 50–70% lower than the values induced 
by intact living leishmania parasites and 90% lower than the total stimulation obtained by 
the T cell mitogen ConA. This suggests their stimulation potential in vitro appears to be 
selectively focus toward a particular subset of lymphocytes which  may be regulatory 
CD8+ T cells as published (O’Daly et al. 2009a; O’Daly et al., 2009b; O’Daly et al., 2010a; 
O’Daly et al.,  2011) 
7.5 The role of IL-10 in parasitic defense and autoimmune disease 
IL-10 plays an important role in many skin autoimmune diseases, and in certain parasitic 
infections, in humans as well as in experimental animals (Weiss et al., 2004). IL-10 
stimulates NK cells cytotoxicity and IL-2 inducing IFNγ and TNFǂ production. In 
addition, IL-10 produced by Th2 cells inhibits IFNγ synthesis by Th1 cells and 
downregulates cellular immunity. Th3 or regulatory T cells produce IL-10 that inhibits 
Th1 and Th2 cell cytokine production, mediating peripheral cell tolerance (Seifert et al., 
2000). Further underscoring the importance of IL-10 is its role in parasitic infections, in 
the persistence of L(L)major in the skin after healing and the therapeutic potential of anti-
IL-10 receptor antibody for sterile cure. (Belkaid et al., 2001)  L. donovani-infected 
BALB/c mice treated with anti-IL-10 receptor had accelerated granuloma formation and 
rapid parasite killing without excessive tissue inflammation (Murray et al., 2002). A 
comparison between cells, cytokines, cellular and humoral immunity in bot diseases is 
presented in Table 2. 
7.6 Relationship between leismaniasis and psoriasis 
How can we reconcile the finding that treatment with a leishmanial antigen vaccine 
targeted at leishmaniasis, results in clinical remission of psoriasis in subjects never 
exposed to Leishmania parasites? Despite some of the obvious differences between the 
diseases, there are some striking similarities: immunity against both diseases starts with 
the same cell types, and also both diseases have similar Th1cytokine patterns at least 
initially, both diseases respond to the Leishmania polyvalent vaccine, AS100-1. It should 
be noted that both trials showed evidence of cellular immunity not humoral immunity. In 
psoriasis, initial interaction of antigens between APC and T cells occurs in the lymph 
nodes. Subsequent psoriatic antigen presentation occurs in psoriatic plaques that 
structurally resemble a lymph node, but are found in the skin. At this stage of psoriatic 
disease, the cellular conformation is quite similar to the granuloma found in the skin after 
Leishmania infection (Table 2). 
Finally, many doors have been opened with the serendipity discovery of Leishmania 
amastigote antigens inducing clinical remission of psoriasis as a systemic disease, which no 
doubt will provide new roads and answers not solved yet. 
Future research and clinical efforts will illuminate many fundamental problems, 
encountered in those terrible illness affecting human beings in all countries on earth. 
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Unknown etiology. Genetically determined 
disease, multiple genes interacting with 
environment involved in the inflammatory 
process manifested as plaques, gutatta, 
palm/plantar, erythrodermia, nails, and 
arthritic forms. 
Infection by metacyclic promastigotes in 
vector (sandfly) that transform immediately 
into intracellular amastigotes in cells of 
vertebrate host, inducing cutaneous, 
mucocutaneous, diffuse and visceral clinical 
forms. 
Starting lesions in epidermis with 
macrophages, monocytes, lymphocytes and 
neutrophiles at Munro sterile abscesses. 
Unknown antigen at immunological 
synapse structured by MHC-TCR receptors 
between T cells and APC with 
costimulatory molecules as LFA-1, ICAM-1, 
CD2, LFA-3 CD28, CD80. Proliferation and 
migration CD4+ T cells from the lymph 
nodes to the dermis regulated by cytokines. 
Dermal CD4+ and epidermal CD8+ cells 
contribute to plaque formation. 
Neutrophiles, lymphocytes, epithelioid cells, 
monocytes, macrophages and fibroblasts 
starts at the site of infection. Leishmania 
antigens at similar immunological synapse  
MHC-TCR receptors between T cells and 
APC with same costimulatory molecules. 
CD4+ and CD8+ cells contribute to IFNǄ and 
TNFǂ production in infected patients and 
healing of lesions. Leishmania antigens 
induce in vitro proliferation and IFNǄ 
production in CD2+ T cells from PBMC in 
individuals that never had contact with 
parasites.  
Cell-cell interactions in skin involve: 
keratinocytes, melanocytes, Langerhans 
cells, dendritic cells, mast cells, naive T 
cells, memory T cells expressing CLA. 
ICAM-1 and E-Selectin receptors on dermal 
endothelial cells. In the epidermis 
neutrophiles and CD8+ T cells with MHCII, 
IL-2 receptor, modulate inflammation. 
Skin immunity delivered by keratinocytes, 
melanocytes , dendritic Langerhans cells, 
mast cells, tissue macrophages, neutrophils, 
dermal dendritic cells and fibroblasts, T cells, 
memory T cells expressing CLA. Similar 
receptors on endothelial cells. Epidermal and 
dermal cells cytokines modulate immune 
response and inflammation after infection. 
TH1 cytokines increase in plaques and 
serum represented by TNFǂ, IFNǄ, IL-6, IL-
8, IL12, and IL-18. High levels of IFNǄ, IL12, 
and IL-18 correlated with disease severity. 
Relative under expression of TH2 cytokines 
IL-4 and IL-10. Dilated blood vessels earliest 
signal within dermal papillae induced by 
keratinocytes pro-angiogenic cytokines.  
Activated macrophages produce: TNFǂ, IL-6, 
IL-18, IFNǄ and high IL-12, inducing a 
protective TH1 immune response in resistant 
mice. TH2 response with IL-4, IL-13, IL-10 
and low or absent IL-12 in susceptible mice. 
Humans with resolving lesions have higher 
ratios of INF/IL4 compared to patients with 
nonhealing lesions. 
Clinical response to IL-10 correlated with 
decreased cutaneous infiltration and 
decrease of IFN, TNF, IL-17, 
IL-8 and CXCR2 in lesions. UV light exerts 
its therapeutic effects by stimulating 
keratinocytes or APC to secrete IL-10. 
Cutaneous IL-10 mRNA is significantly 
lower in psoriasis.  
IL-10 promotes disease progression in 
cutaneous leishmaniasis. Chronic infections 
in humans and mice associated with 
generation of CD4+ T cells expressing IL-10. 
IL-10 responses and the generation of 
functionally impaired CD8+ T-cells permit 
parasites persistence in the host.  
Table 2. Comparison of pathogenesis between Psoriasis and leishmaniasis 
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